ICON plcG4705A100IE000571120907/22/2025Elect Director Ciaran MurrayDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director Steve CutlerDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director Ronan MurphyDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director John ClimaxDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director Julie O'NeillDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director Eugene McCagueDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director Linda GraisDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Elect Director Anne WhitakerDIRECTOR ELECTIONSISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Ratify Ernst & Young as Auditors and Authorize Their RemunerationAUDIT-RELATEDISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Authorize Issue of EquityCAPITAL STRUCTUREISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Authorize Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Authorize Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Authorize Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER66229.0000000FOR66229.000000FORS000002088ICON plcG4705A100IE000571120907/22/2025Approve the Price Range for the Reissuance of SharesCAPITAL STRUCTUREISSUER66229.0000000FOR66229.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Dominic J. CarusoDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Lynne M. DoughtieDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: W. Roy DunbarDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Deborah Dunsire, M.D.DIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Julie L. Gerberding, M.D., M.P.H.DIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: James H. HintonDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Donald R. KnaussDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Bradley E. LermanDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Maria N. MartinezDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Kevin M. OzanDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Brian S. TylerDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Election of Twelve Directors for a One-Year Term: Kathleen Wilson-ThompsonDIRECTOR ELECTIONSISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2026AUDIT-RELATEDISSUER42024.0000000FOR42024.000000FORS000002088McKesson Corporation58155Q103US58155Q103107/30/2025Advisory Vote to Approve the Company's Executive CompensationSECTION 14A SAY-ON-PAY VOTESISSUER42024.0000000FOR42024.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Business Combination Proposal - to consider and vote upon a proposal to approve, as an ordinary resolution, the Business Combination Agreement, dated February 28, 2028 (as amended by Amendment No. 1 to the Business Combination Agreement, dated as of June 17, 2025, and as it may be further amended, restated, supplemented, or otherwise modified from time to time, the "Business Combination Agreement"), by and among Helix Acquisition Corp. II, a Cayman Islands exempted company ("Helix"), Helix II Merger Sub, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Helix ("Merger Sub") and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation ("BBOT"), and the transactions contemplated thereby, pursuant to which the following will occur: (1) the domestication of Helix as a Delaware corporation, in which Helix will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation in accordance with the amended and restated memorandum and articles of association of Helix (the "Helix Articles"), Section 388 of the Delaware General Corporation Law (the "DGCL") and Part XII of the Companies Act (As Revised) of the Cayman Islands (the "Cayman Companies Act") (the "Domestication"); (2) the merger of Merger Sub with and into BBOT with BBOT surviving the merger as a wholly-owned subsidiary of Helix (the "Merger"), in accordance with the Business Combination Agreement and DGCL; and (3) the other transactions contemplated by the Business Combination Agreement and documents related thereto (such transactions, together with the Domestication and the Merger, the "Business Combination"), all as described in more detail in the proxy statement/prospectus. In connection with the consummation of the Business Combination (the "Closing" and the date of the Closing, the "Closing Date"), Helix will be renamed BridgeBio Oncology Therapeutics, Inc. ("PubCo"). A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as Annex A.EXTRAORDINARY TRANSACTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Domestication Proposal - to consider and vote upon a proposal to approve, by special resolution, the deregistration of Helix from the Registrar of Companies in the Cayman Islands (the "Cayman Registrar") and transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation in accordance with the Helix Articles, Section 388 of the DGCL, and Part XII of the Cayman Companies Act.EXTRAORDINARY TRANSACTIONSCORPORATE GOVERNANCEISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Stock Issuance Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, including for purposes of complying with the applicable provisions of Nasdaq Listing Rules 5635(a), (b) and (d), the issuance or potential issuance of (i) shares of common stock, par value $0.0001 per share, of PubCo (the "PubCo Common Stock") to the shareholders of Helix in the Domestication and stockholders of BBOT in the Merger pursuant to the Business Combination Agreement, (ii) shares of PubCo Common Stock to the PIPE Investors in the PIPE Investment pursuant to the Subscription Agreements, and (iii) any other issuances of PubCo Common Stock and securities convertible into or exercisable for PubCo Common Stock pursuant to subscription, purchase or similar agreements Helix has entered, or may enter, into prior to Closing.CAPITAL STRUCTUREISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Organizational Documents Proposal - to consider and vote upon a proposal to approve, by special resolution, the proposed new certificate of incorporation of PubCo (the "Pub Co Charter") and the proposed new bylaws of PubCo (the "PubCo Bylaws" and, together with the PubCo Charter, the "PubCo Organizational Documents") in connection with the Business Combination. The form of each of the PubCo Charter and the PubCo Bylaws is attached to the proxy statement/prospectus as Annex I and Annex J, respectively.CORPORATE GOVERNANCEISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Advisory Organizational Documents Proposals - to consider and vote upon the following six separate proposals to approve an ordinary resolution on a non-binding advisory basis only the following material differences between the Helix Articles and the PubCo Organizational Documents: Authorized Shares - A proposal to amend the Helix Articles to authorize the change in the authorized capital stock of Helix from (i) 500,000,000 Helix Class A Shares, 50,000,000 Helix Class B Shares and 5,000,000 preference shares, par value $0.0001 per share, to (ii) 500,000,000 shares of PubCo Common Stock and 10,000,000 shares of undesignated PubCo preferred stock;CAPITAL STRUCTUREISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Exclusive Forum Provision - A proposal to amend the Helix Articles to authorize adopting Delaware as the exclusive forum for certain stockholder litigation;SHAREHOLDER RIGHTS AND DEFENSESCORPORATE GOVERNANCEISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Adoption of Supermajority Vote Requirement to Amend the Proposed Organizational Documents - A proposal to amend the Helix Articles to approve provisions requiring the affirmative vote of at least (i) two-thirds of the outstanding shares of capital stock entitled to vote to adopt, amend or repeal the PubCo Bylaws and (ii) a majority of PubCo's then outstanding common stock (except where a lower threshold is provided by the DGCL) for amendments to the PubCo Charter;CORPORATE GOVERNANCEISSUER878945.0000000AGAINST878945.000000AGAINSTS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Removal of Directors - A proposal to amend the Helix Articles to approve provisions permitting the removal of a director only for cause and only by the affirmative vote of not less than two-thirds of the outstanding shares entitled to vote at an election of directors, voting together as a single class;CORPORATE GOVERNANCEISSUER878945.0000000AGAINST878945.000000AGAINSTS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Action by Written Consent of Stockholders - A proposal to amend the Helix Articles to approve provisions requiring stockholders to take action at an annual or special meeting and prohibiting stockholder action by written consent in lieu of a meeting;CORPORATE GOVERNANCEISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Other Changes in Connection with Adoption of the proposed PubCo Organizational Documents - A proposal to amend the Helix Articles to authorize (1) changing the corporate name from "Helix Acquisition Corp. II" to "BridgeBio Oncology Therapeutics, Inc.", (2) making PubCo's corporate existence perpetual, and (3) removing certain provisions related to Helix's status as a blank check company that will no longer be applicable upon consummation of the Business Combination.CORPORATE GOVERNANCEISSUER878945.0000000AGAINST878945.000000AGAINSTS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Incentive Plan Proposal - to consider and vote upon a proposal to approve, by ordinary resolution, the BridgeBio Oncology Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "PubCo Incentive Plan").COMPENSATIONISSUER878945.0000000AGAINST878945.000000AGAINSTS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The ESPP Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the BridgeBio Oncology Therapeutics, Inc. 2025 Employee Stock Purchase Plan (the "ESPP").COMPENSATIONISSUER878945.0000000AGAINST878945.000000AGAINSTS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Eli Wallace, Ph.D.DIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Neil Kumar, Ph.D.DIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Frank McCormick, Ph.D., F.R.S., D. Sc.DIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Praveen Tipirneni, M.D.DIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Michelle DoigDIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Bihua ChenDIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Raymond Kelleher, M.D., Ph.D.DIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025Director Election Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the election of eight directors to serve on the PubCo board of directors until their respective successors are duly elected and qualified: Jake Bauer, M.B.A.DIRECTOR ELECTIONSISSUER878945.0000000FOR878945.000000FORS000002088Helix Acquisition Corp. II107924102US107924102208/04/2025The Adjournment Proposal - To consider and vote upon a proposal to approve, by ordinary resolution, the adjournment of the EGM to a later date or dates, if necessary or desirable.CORPORATE GOVERNANCEISSUER878945.0000000AGAINST878945.000000AGAINSTS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Paul B. Bolno, M.D., MBADIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Mark H. N. Corrigan, M.D.DIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Christian HenryDIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Peter Kolchinsky, Ph.D.DIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Adrian RawcliffeDIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Ken TakanashiDIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Aik Na TanDIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Gregory L. Verdine, Ph.D.DIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025The election of the nominees for director: Heidi L. Wagner, J.D.DIRECTOR ELECTIONSISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve the re-appointment of KPMG LLP to serve as our independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2025, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP's remuneration for services provided through the date of our 2026 Annual General Meeting of Shareholders.AUDIT-RELATEDISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve our payment of cash and equity-based compensation to non-employee directors for service on the Board of Directors and its committees, in the manner and on the basis set forth under "Proposal 3: Non-Employee Directors' Compensation" in the proxy statement.COMPENSATIONISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, in the manner and on the basis as set forth under "Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as amended" in the proxy statement.COMPENSATIONISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.CAPITAL STRUCTUREISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, by a non-binding advisory vote, the compensation of our named executive officers as disclosed in the proxy statementSECTION 14A SAY-ON-PAY VOTESISSUER1079679.0000000FOR1079679.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471608/05/2025To approve, on a non-binding, advisory basis only, the frequency of holding future shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1079679.0000000ONE YEAR1079679.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.DIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Elizabeth BarrettDIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Cynthia M. ButittaDIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Stuart Holden, M.D.DIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: James A. Robinson, Jr.DIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Leana S. Wen, M.D., M.Sc.DIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Daniel G. WildmanDIRECTOR ELECTIONSISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To approve amendments to the Company's 2024 non-employee director and officer compensation policy to, among other things, increase the equity compensation payable to our executive officers and non-employee directors.COMPENSATIONISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To approve amendments to the Company's 2017 Equity Incentive Plan to, among other things, increase the number of ordinary shares authorized for issuance under the plan by 2,750,000 shares.COMPENSATIONISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting.SECTION 14A SAY-ON-PAY VOTESISSUER250762.0000000FOR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER250762.0000000ONE YEAR250762.000000FORS000002088UroGen Pharma Ltd.M96088105IL001140714008/26/2025To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company's auditor until the Company's 2026 annual meeting of shareholders.AUDIT-RELATEDISSUER250762.0000000FOR250762.000000FORS000002088Kestra Medical Technologies, Ltd.G52441105BMG52441105209/03/2025The election of Conor Hanley and Elizabeth Kwo to serve as Class I directors until the Company's 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Conor HanleyDIRECTOR ELECTIONSISSUER480387.0000000FOR480387.000000FORS000002088Kestra Medical Technologies, Ltd.G52441105BMG52441105209/03/2025The election of Conor Hanley and Elizabeth Kwo to serve as Class I directors until the Company's 2028 annual meeting of shareholders and until their successors are duly elected and qualified: Elizabeth KwoDIRECTOR ELECTIONSISSUER480387.0000000FOR480387.000000FORS000002088Kestra Medical Technologies, Ltd.G52441105BMG52441105209/03/2025The ratification of the appointment of PricewaterhouseCoopers as the Company's independent registered accounting firm for the fiscal year ending April 30, 2026.AUDIT-RELATEDISSUER480387.0000000FOR480387.000000FORS000002088Kestra Medical Technologies, Ltd.G52441105BMG52441105209/03/2025The approval of the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan.COMPENSATIONISSUER480387.0000000FOR480387.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025Election of Directors: Kapil DhingraDIRECTOR ELECTIONSISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025Election of Directors: Christy OligerDIRECTOR ELECTIONSISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025Election of Directors: Joseph SlatteryDIRECTOR ELECTIONSISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025Election of Directors: Michael GollerDIRECTOR ELECTIONSISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025Election of Directors: Philip Astley-SparkeDIRECTOR ELECTIONSISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2026.AUDIT-RELATEDISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.'s named executive officers for the fiscal year ended March 31, 2025.SECTION 14A SAY-ON-PAY VOTESISSUER2095368.0000000FOR2095368.000000FORS000002088Replimune Group, Inc.76029N106US76029N106309/03/2025To approve an amendment to Replimune Group, Inc.'s 2018 Omnibus Incentive Compensation Plan (the "Plan Amendment").COMPENSATIONISSUER2095368.0000000AGAINST2095368.000000AGAINSTS000002088Roivant Sciences Ltd.G76279101BMG76279101709/10/2025To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Matthew GlineDIRECTOR ELECTIONSISSUER931478.0000000FOR931478.000000FORS000002088Roivant Sciences Ltd.G76279101BMG76279101709/10/2025To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith ManchesterDIRECTOR ELECTIONSISSUER931478.0000000FOR931478.000000FORS000002088Roivant Sciences Ltd.G76279101BMG76279101709/10/2025To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa EpperlyDIRECTOR ELECTIONSISSUER931478.0000000FOR931478.000000FORS000002088Roivant Sciences Ltd.G76279101BMG76279101709/10/2025To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2026, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2026, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2026.AUDIT-RELATEDISSUER931478.0000000FOR931478.000000FORS000002088Roivant Sciences Ltd.G76279101BMG76279101709/10/2025To cast a non-binding, advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER931478.0000000AGAINST931478.000000AGAINSTS000002088Heron Therapeutics, Inc.427746102US427746102010/13/2025To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock in connection with the conversion of convertible senior unsecured promissory notes due 2031 held by several non-affiliated purchasers, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of common stock issued and outstanding prior to such issuance.CAPITAL STRUCTUREISSUER1238460.0000000FOR1238460.000000FORS000002088Heron Therapeutics, Inc.427746102US427746102010/13/2025To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's common stock in connection with the conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which could, under certain circumstances that may occur in the future, exceed 19.99% of the number of shares of common stock issued and outstanding prior to such issuance.CAPITAL STRUCTUREISSUER1238460.0000000FOR1238460.000000FORS000002088AstraZeneca PLC046353108US046353108911/03/2025Adopt New Articles of AssociationCORPORATE GOVERNANCEISSUER3283838.0000000FOR3283838.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Robert W. AzelbyDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Michelle M. BrennanDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Sheri H. EdisonDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: David C. EvansDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Patricia A. Hemingway HallDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Jason M. HollarDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Akhil JohriDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Gregory B. KennyDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Nancy KilleferDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Christine A. MundkurDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Robert W. MusslewhiteDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025Election of Directors: Sudhakar RamakrishnaDIRECTOR ELECTIONSISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025To approve, on a non-binding advisory basis, the compensation of our named executive officersSECTION 14A SAY-ON-PAY VOTESISSUER346080.0000000FOR346080.000000FORS000002088Cardinal Health, Inc.14149Y108US14149Y108211/05/2025To ratify the appointment of Ernst & Young LLP as our independent auditor for the fiscal year ending June 30, 2026AUDIT-RELATEDISSUER346080.0000000FOR346080.000000FORS000002088argenx SE04016X101US04016X101911/18/2025Approve Remuneration PolicyCOMPENSATIONISSUER662719.0000000FOR662719.000000FORS000002088Waters Corporation941848103US941848103501/27/2026To approve the issuance of shares of common stock, par value $0.01 per share, of the Company (the "Waters Common Stock"), pursuant to the Agreement and Plan of Merger, dated as of July 13, 2025, by and among the Company, Becton, Dickinson and Company, Augusta SpinCo Corporation and Beta Merger Sub, Inc., as amended from time to time (the "Share Issuance Proposal").EXTRAORDINARY TRANSACTIONSISSUER79495.0000000FOR79495.000000FORS000002088Waters Corporation941848103US941848103501/27/2026To approve the adjournment of the Special Meeting, if necessary, (a) to solicit additional proxies in the event there are not sufficient votes at the time of the Special Meeting to approve the Share Issuance Proposal, (b) if there are insufficient shares of Waters Common Stock represented (either in person via the Internet or by proxy) to constitute a quorum necessary to conduct business at the Special Meeting or (c) to allow reasonable time for the filing or mailing of any supplemental or amended disclosures that the Company has determined, based on the advice of outside legal counsel, are reasonably likely to be required under applicable law and for such supplemental or amended disclosures to be disseminated and reviewed by the Company's shareholders prior to the Special Meeting.CORPORATE GOVERNANCEISSUER79495.0000000AGAINST79495.000000AGAINSTS000002088MediWound Ltd.M68830112IL001131630902/19/2026Increase Number of Ordinary Shares Under Company's Incentive PlanCOMPENSATIONISSUER134019.0000000FOR134019.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Werner BaumannDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Frank K. ClyburnDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Ellen G. CooperDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: D. Mark DurcanDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Lon R. GreenbergDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Lorence H. Kim, M.D.DIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Robert P. MauchDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Redonda G. Miller, M.D.DIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Dennis M. NallyDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Lori J. RyerkerkDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Election of eleven directors: Lauren M. TylerDIRECTOR ELECTIONSISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Advisory vote to approve the fiscal 2025 compensation of Cencora, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER202134.0000000FOR202134.000000FORS000002088Cencora, Inc.03073E105US03073E105503/05/2026Ratify the appointment of Ernst & Young LLP as Cencora, Inc.'s independent registered public accounting firm for fiscal 2026.AUDIT-RELATEDISSUER202134.0000000FOR202134.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: Christopher AnzaloneDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: Mauro FerrariDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: Hongbo LuDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: Adeoye OlukotunDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: Michael S. PerryDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: Victoria VakienerDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Election of Directors: William WaddillDIRECTOR ELECTIONSISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Advisory Vote to Approve Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER326985.0000000AGAINST326985.000000AGAINSTS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Approval of the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan.COMPENSATIONISSUER326985.0000000FOR326985.000000FORS000002088Arrowhead Pharmaceuticals, Inc.04280A100US04280A100703/19/2026Ratification of the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2026.AUDIT-RELATEDISSUER326985.0000000FOR326985.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Elect Chair of MeetingCORPORATE GOVERNANCEISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Accept Financial Statements and Statutory Reports; Approve Discharge of Management and BoardCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Approve Treatment of Net LossCAPITAL STRUCTUREISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Reelect Albert Cha as DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Reelect Lars Holtug as DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Reelect Jan Moller Mikkelsen as DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Reelect Lisa Jane Morrison as DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Reelect William Carl Fairey Jr as DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Reelect Siham Imani as DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Elect Jean-Jacques Bienaime as New DirectorDIRECTOR ELECTIONSISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Ratify Deloitte as AuditorAUDIT-RELATEDISSUER683903.0000000FOR683903.000000FORS000002088Ascendis Pharma A/SK08588103DK006061575503/23/2026Authorize Share Repurchase ProgramCAPITAL STRUCTUREISSUER683903.0000000FOR683903.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Approve Allocation of Income, with a Final Dividend of JPY 147CAPITAL STRUCTUREISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Okuda, OsamuDIRECTOR ELECTIONSISSUER1080300.0000000AGAINST1080300.000000AGAINSTS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Taniguchi, IwaakiDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Iikura, HitoshiDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Tateishi, FumioDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Teramoto, HideoDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Mitani, KinukoDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Thomas SchineckerDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Teresa A. GrahamDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Elect Director Boris L. ZaitraDIRECTOR ELECTIONSISSUER1080300.0000000FOR1080300.000000FORS000002088Chugai Pharmaceutical Co., Ltd.J06930101JP351940000003/26/2026Approve Trust-Type Equity Compensation PlanCOMPENSATIONISSUER1080300.0000000FOR1080300.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Approve DividendsCAPITAL STRUCTUREISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Appoint KPMG LLP as AuditorsAUDIT-RELATEDISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise Board to Fix Remuneration of AuditorsAUDIT-RELATEDISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Michel Demare as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Pascal Soriot as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Aradhana Sarin as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Philip Broadley as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Euan Ashley as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Birgit Conix as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Rene Haas as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Karen Knudsen as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Diana Layfield as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Anna Manz as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Sheri McCoy as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Tony Mok as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Re-elect Marcus Wallenberg as DirectorDIRECTOR ELECTIONSISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Approve Remuneration ReportCOMPENSATIONISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Amend Performance Share PlanCOMPENSATIONISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise UK Political Donations and ExpenditureOTHER SOCIAL ISSUESISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise Issue of EquityCAPITAL STRUCTUREISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise Issue of Equity without Pre-emptive RightsCAPITAL STRUCTUREISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital InvestmentCAPITAL STRUCTUREISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise Market Purchase of Ordinary SharesCAPITAL STRUCTUREISSUER1765704.0000000FOR1765704.000000FORS000002088AstraZeneca PLCG0593M107GB000989529204/09/2026Authorise the Company to Call General Meeting with Two Weeks' NoticeCORPORATE GOVERNANCEISSUER1765704.0000000FOR1765704.000000FORS000002088Bio-Rad Laboratories, Inc.090572207US090572207204/21/2026Nominees: Melinda LitherlandDIRECTOR ELECTIONSISSUER70985.0000000AGAINST70985.000000AGAINSTS000002088Bio-Rad Laboratories, Inc.090572207US090572207204/21/2026Nominees: Arnold A. PinkstonDIRECTOR ELECTIONSISSUER70985.0000000AGAINST70985.000000AGAINSTS000002088Bio-Rad Laboratories, Inc.090572207US090572207204/21/2026Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.AUDIT-RELATEDISSUER70985.0000000FOR70985.000000FORS000002088Bio-Rad Laboratories, Inc.090572207US090572207204/21/2026Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER70985.0000000FOR70985.000000FORS000002088Bio-Rad Laboratories, Inc.090572207US090572207204/21/2026Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.COMPENSATIONISSUER70985.0000000FOR70985.000000FORS000002088Bio-Rad Laboratories, Inc.090572207US090572207204/21/2026Stockholder proposal regarding dual class capital structure.SHAREHOLDER RIGHTS AND DEFENSESCAPITAL STRUCTURESECURITY HOLDER70985.0000000FOR70985.000000AGAINSTS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: David M. CordaniDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Brian C. EvankoDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Eric J. FossDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Neesha HathiDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Michael J. HenniganDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: George KurianDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Kathleen M. MazzarellaDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Mark B. McClellan, M.D., Ph.D.DIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Philip O. Ozuah, M.D., Ph.D.DIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Kimberly A. RossDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Eric C. WisemanDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Election of Directors: Donna F. ZarconeDIRECTOR ELECTIONSISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Advisory approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Ratification of the appointment of PricewaterhouseCoopers LLP as The Cigna Group's independent registered public accounting firm for 2026AUDIT-RELATEDISSUER311343.0000000FOR311343.000000FORS000002088The Cigna Group125523100US125523100304/22/2026Shareholder Proposal - Shareholder Right to Act by Written ConsentCORPORATE GOVERNANCESECURITY HOLDER311343.0000000AGAINST311343.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Thomas F. Frist IIIDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Samuel N. HazenDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: John W. Chidsey, IIIDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Nancy-Ann DeParleDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: William R. FristDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Hugh F. JohnstonDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Michael W. MichelsonDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Wayne J. Riley, M.D.DIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Election of Directors: Andrea B. SmithDIRECTOR ELECTIONSISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER209100.0000000FOR209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences.OTHER SOCIAL ISSUESSECURITY HOLDER209100.0000000AGAINST209100.000000FORS000002088HCA Healthcare, Inc.40412C101US40412C101804/23/2026Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent.CORPORATE GOVERNANCESECURITY HOLDER209100.0000000AGAINST209100.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): Ari BousbibDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): Carol J. BurtDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): John G. DanhaklDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): James A. FasanoDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): Colleen A. GogginsDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): William G. Kaelin Jr., M.D.DIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): John M. Leonard, M.D.DIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): Leslie Wims MorrisDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026The election of each of the director nominees listed below (a through i): Sheila A. StampsDIRECTOR ELECTIONSISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).SECTION 14A SAY-ON-PAY VOTESISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER229587.0000000FOR229587.000000FORS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026Approve the adoption of the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan.COMPENSATIONISSUER229587.0000000AGAINST229587.000000AGAINSTS000002088IQVIA Holdings Inc.46266C105US46266C105304/23/2026If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles.CORPORATE GOVERNANCESECURITY HOLDER229587.0000000AGAINST229587.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Mary C. BeckerleDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Jennifer A. DoudnaDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Joaquin DuatoDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Marillyn A. HewsonDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Paula A. JohnsonDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Hubert JolyDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Mark B. McClellanDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: John G. MorikisDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Daniel E. PintoDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Mark A. WeinbergerDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Nadja Y. WestDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Election of Directors: Eugene A. WoodsDIRECTOR ELECTIONSISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER233720.0000000FOR233720.000000FORS000002088Johnson & Johnson478160104US478160104604/23/2026Independent Board ChairCORPORATE GOVERNANCESECURITY HOLDER233720.0000000AGAINST233720.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Michael T. HeffernanDIRECTOR ELECTIONSISSUER1276302.0000000FOR1276302.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Irina Antonijevic, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1276302.0000000FOR1276302.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/28/2026Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Robert J. HuginDIRECTOR ELECTIONSISSUER1276302.0000000FOR1276302.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/28/2026Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2026.AUDIT-RELATEDISSUER1276302.0000000FOR1276302.000000FORS000002088Biohaven Ltd.G1110E107VGG1110E107904/28/2026A non-binding advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1276302.0000000FOR1276302.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Peter Barrett, PhDDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Samuel R. ChapinDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Michael A. KlobucharDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Michelle McMurry-Heath, MD, PhDDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Alexis P. MichasDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Prahlad R. Singh, PhDDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Sophie V. Vandebroek, PhDDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Michel VounatsosDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Frank Witney, PhDDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To elect ten nominees for director for terms of one year each: Pascale WitzDIRECTOR ELECTIONSISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To ratify the selection of Deloitte & Touche LLP as Revvity's independent registered public accounting firm for the current fiscal year.AUDIT-RELATEDISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To approve, by non-binding advisory vote, our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To approve an amendment to Revvity's Amended and Restated By-Laws to Allow Shareholders Owning 25% of Our Stock to Call a Special Meeting.CORPORATE GOVERNANCEISSUER283926.0000000FOR283926.000000FORS000002088Revvity, Inc.714046109US714046109304/28/2026To approve the shareholder proposal regarding Executives to Retain Significant Stock.COMPENSATIONSECURITY HOLDER283926.0000000AGAINST283926.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: David C. HabigerDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Edward J. LudwigDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Michael F. MahoneyDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Jessica L. MegaDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Susan E. MoranoDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Cheryl PegusDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Cathy R. SmithDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Christophe P. WeberDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: David S. WichmannDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Proposal to elect ten Directors: Ellen M. ZaneDIRECTOR ELECTIONSISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026To amend our Employee Stock Purchase Plan to increase the number of shares reserved for issuance.COMPENSATIONISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026To amend our Certificate of Incorporation to remove supermajority voting provisions.CORPORATE GOVERNANCEISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026To amend our Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law.CORPORATE GOVERNANCEISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026To amend our Certificate of Incorporation and By-Laws to permit stockholders holding 25% of our common stock to call a special meeting of stockholders.CORPORATE GOVERNANCEISSUER1254857.0000000FOR1254857.000000FORS000002088Boston Scientific Corporation101137107US101137107704/30/2026Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."CORPORATE GOVERNANCESECURITY HOLDER1254857.0000000AGAINST1254857.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.DIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.DIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.DIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. KramerDIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.DIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish ManwaniDIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'DayDIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. RodriguezDIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony WeltersDIRECTOR ELECTIONSISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan.COMPENSATIONISSUER2168074.0000000FOR2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting.CORPORATE GOVERNANCESECURITY HOLDER2168074.0000000AGAINST2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting.OTHER SOCIAL ISSUESSECURITY HOLDER2168074.0000000AGAINST2168074.000000FORS000002088Gilead Sciences, Inc.375558103US375558103604/30/2026To vote on a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics, if properly presented at the Annual Meeting.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER2168074.0000000AGAINST2168074.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Election of Class II Directors: Gary L. EllisDIRECTOR ELECTIONSISSUER138578.0000000FOR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Election of Class II Directors: Georgia MelenikiotouDIRECTOR ELECTIONSISSUER138578.0000000FOR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Election of Class II Directors: Dana G. Mead, Jr.DIRECTOR ELECTIONSISSUER138578.0000000FOR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER138578.0000000FOR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER138578.0000000FOR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Approval, on a advisory (non-binding) basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER138578.0000000ONE YEAR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Approval of an amendment to the Company's Seventh Amended and Restated Certificate of Incorporation to phase out the classified Board structure and provide for the annual election of all directors beginning with the Company's 2029 annual meeting of stockholders.SHAREHOLDER RIGHTS AND DEFENSESISSUER138578.0000000FOR138578.000000FORS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Approval of an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan.COMPENSATIONISSUER138578.0000000AGAINST138578.000000AGAINSTS000002088Inspire Medical Systems, Inc.457730109US457730109004/30/2026Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal No. 5 and/or Proposal No. 6.CORPORATE GOVERNANCEISSUER138578.0000000AGAINST138578.000000AGAINSTS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Craig H. Barratt, Ph.D.DIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Joseph C. BeeryDIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Lewis ChewDIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Gary S. Guthart, Ph.D.DIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Sreelakshmi KolliDIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Amy L. Ladd, M.D.DIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Keith R. Leonard, Jr.DIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Jami Dover NachtsheimDIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: Monica P. Reed, M.D.DIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026Election of Directors: David J. RosaDIRECTOR ELECTIONSISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER905473.0000000FOR905473.000000FORS000002088Intuitive Surgical, Inc.46120E602US46120E602304/30/2026To approve the amendment and restatement of the Company's Amended and Restated 2010 Incentive Award Plan.COMPENSATIONISSUER905473.0000000FOR905473.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term: Carolyn BertozziDIRECTOR ELECTIONSISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term: William Kaelin, Jr.DIRECTOR ELECTIONSISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term: Jon MoellerDIRECTOR ELECTIONSISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Election of the following directors, each to serve a three-year term: David RicksDIRECTOR ELECTIONSISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2026.AUDIT-RELATEDISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Approval of amendments to the company's articles of incorporation to eliminate the classified board structure.SHAREHOLDER RIGHTS AND DEFENSESISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Approval of amendments to the company's articles of incorporation to eliminate supermajority voting provisions.CORPORATE GOVERNANCEISSUER1315236.0000000FOR1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair.CORPORATE GOVERNANCESECURITY HOLDER1315236.0000000AGAINST1315236.000000FORS000002088Eli Lilly and Company532457108US532457108305/04/2026Shareholder proposal to prepare an annual lobbying report.OTHER SOCIAL ISSUESSECURITY HOLDER1315236.0000000AGAINST1315236.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Mark A. ButhmanDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: William F. FeeheryDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Robert F. FrielDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Eric M. GreenDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Janet B. HaugenDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Molly E. JosephDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Deborah L. V. KellerDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Myla P. Lai-GoldmanDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Stephen H. LockhartDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Douglas A. MichelsDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Election of Directors: Paolo PucciDIRECTOR ELECTIONSISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Ratification of the appointment of our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER72315.0000000FOR72315.000000FORS000002088West Pharmaceutical Services, Inc.955306105US955306105505/04/2026Shareholder proposal regarding an independent Board Chair policy.CORPORATE GOVERNANCESECURITY HOLDER72315.0000000AGAINST72315.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Nancy C. AndrewsDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Steven BargDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Abraham CeesayDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Mark EnyedyDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: James C. FosterDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Birgit GirshickDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Paul GravesDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Reshema Kemps-PolancoDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: George LladoDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Martin MackayDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Craig B. ThompsonDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Election of Directors: Virginia WilsonDIRECTOR ELECTIONSISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Advisory Approval of 2025 Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/20262026 Long-Term Incentive PlanCOMPENSATIONISSUER80291.0000000FOR80291.000000FORS000002088Charles River Laboratories International, Inc.159864107US159864107405/05/2026Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2026AUDIT-RELATEDISSUER80291.0000000FOR80291.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Rainer M. BlairDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Feroz DewanDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Linda FillerDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Charles W. LamannaDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri L. ListDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Mitchell P. RalesDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Steven M. RalesDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane SandersDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Alan G. SpoonDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Raymond C. Stevens, Ph.D.DIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To elect the eleven directors named in the attached Proxy Statement to hold office until the 2027 Annual Meeting of Shareholders and until their successors are elected and qualified: Elias A. Zerhouni, MDDIRECTOR ELECTIONSISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To approve on an advisory basis the Company's named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1318899.0000000FOR1318899.000000FORS000002088Danaher Corporation235851102US235851102805/05/2026To approve the Company's Amended and Restated Omnibus Incentive Plan.COMPENSATIONISSUER1318899.0000000FOR1318899.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Approve Remuneration ReportCOMPENSATIONISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Approve Allocation of Income to the Retained Earnings of the CompanyCAPITAL STRUCTUREISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Approve Discharge of Executive DirectorsCORPORATE GOVERNANCEISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Approve Discharge of Non-Executive DirectorsCORPORATE GOVERNANCEISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Elect Karen Massey as Executive DirectorDIRECTOR ELECTIONSISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Elect Tim Van Hauwermeiren as Non-Executive DirectorDIRECTOR ELECTIONSISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Reelect Ana Cespedes as Non-Executive DirectorDIRECTOR ELECTIONSISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Reelect Camilla Sylvest as Non-Executive DirectorDIRECTOR ELECTIONSISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Reelect Pamela Klein as Non-Executive DirectorDIRECTOR ELECTIONSISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Grant Board Authority to Issue Shares Up to 10 Percent of Issued Capital and Limit/Exclude Preemptive RightsCAPITAL STRUCTUREISSUER445470.0000000FOR445470.000000FORS000002088argenx SE04016X101US04016X101905/06/2026Ratify Ernst & Young Accountants LLP as AuditorsAUDIT-RELATEDISSUER445470.0000000FOR445470.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Reelect Nachum Shamir as DirectorDIRECTOR ELECTIONSISSUER62181.0000000FOR62181.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Reelect Vickie R. Driver as DirectorDIRECTOR ELECTIONSISSUER62181.0000000FOR62181.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Reelect David Fox as DirectorDIRECTOR ELECTIONSISSUER62181.0000000FOR62181.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Reelect Shmuel (Milky) Rubinstein as DirectorDIRECTOR ELECTIONSISSUER62181.0000000FOR62181.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Reelect Stephen T. Wills as DirectorDIRECTOR ELECTIONSISSUER62181.0000000FOR62181.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Reappoint Somekh Chaikin, a member firm of KPMG as Auditors and Authorize Board to Fix Their RemunerationAUDIT-RELATEDISSUER62181.0000000FOR62181.000000FORS000002088MediWound Ltd.M68830112IL001131630905/06/2026Approve 2025 Annual Cash Bonus to Ofer Gonen, CEOCOMPENSATIONISSUER62181.0000000FOR62181.000000FORS000002088Moderna, Inc.60770K107US60770K107905/06/2026To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Sandra Horning, M.D.DIRECTOR ELECTIONSISSUER803677.0000000FOR803677.000000FORS000002088Moderna, Inc.60770K107US60770K107905/06/2026To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Abbas HussainDIRECTOR ELECTIONSISSUER803677.0000000FOR803677.000000FORS000002088Moderna, Inc.60770K107US60770K107905/06/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER803677.0000000AGAINST803677.000000AGAINSTS000002088Moderna, Inc.60770K107US60770K107905/06/2026To approve, on a non-binding, advisory basis, the frequency of future non-binding advisory votes to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER803677.0000000ONE YEAR803677.000000FORS000002088Moderna, Inc.60770K107US60770K107905/06/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER803677.0000000FOR803677.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Barbara L. BrasierDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Leo P. GrohowskiDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Stephen H. LockhartDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Steven J. OrlandoDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Ronna E. RomneyDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Richard M. SchapiroDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Francis S. SoistmanDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Dale B. WolfDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Richard C. ZoreticDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To elect ten directors to hold office until the 2027 Annual Meeting: Joseph M. ZubretskyDIRECTOR ELECTIONSISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To consider and approve an amendment to the Company's 2025 Equity Incentive Plan to increase the number of shares available for issuance under such plan.COMPENSATIONISSUER87379.0000000FOR87379.000000FORS000002088Molina Healthcare, Inc.60855R100US60855R100505/06/2026To consider and approve an amendment to the Company's Certificate of Incorporation to permit stockholders to call special stockholders meetings.CORPORATE GOVERNANCEISSUER87379.0000000FOR87379.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Mary K. BrainerdDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Giovanni Caforio, M.D.DIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Kevin A. LoboDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Emmanuel P. MacedaDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Sherilyn S. McCoyDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Rachel M. RuggeriDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Andrew K. SilvernailDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Lisa M. Skeete TatumDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Ronda E. StrykerDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Election Directors: Rajeev SuriDIRECTOR ELECTIONSISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2026.AUDIT-RELATEDISSUER1177166.0000000FOR1177166.000000FORS000002088Stryker Corporation863667101US863667101305/06/2026Advisory Vote to Approve Named Executive Officer Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1177166.0000000FOR1177166.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Leslie C. DavisDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: David T. Feinberg, MDDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Kieran T. GallahueDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Leslie S. HeiszDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Paul A. LaVioletteDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Steven R. LorangerDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Ramona SequeiraDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Nicholas J. ValerianiDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Election of Directors: Bernard ZovighianDIRECTOR ELECTIONSISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTESISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Ratification of Appointment of Independent Registered Public Accounting FirmAUDIT-RELATEDISSUER502146.0000000FOR502146.000000FORS000002088Edwards Lifesciences Corporation28176E108US28176E108205/07/2026Approval of the Amended and Restated Long-Term Stock Incentive Compensation ProgramCOMPENSATIONISSUER502146.0000000FOR502146.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Greg D. CarmichaelDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Edward M. Christie IIIDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Cain A. HayesDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Joan E. HermanDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Leslye G. KatzDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Kevin J. O'ConnorDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Christopher R. ReidyDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Nancy M. SchlichtingDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Mark J. TarrDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Election of ten nominees to the Board of Directors to serve until our 2027 Annual Meeting of Stockholders: Terrance WilliamsDIRECTOR ELECTIONSISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER154409.0000000FOR154409.000000FORS000002088Encompass Health Corporation29261A100US29261A100705/07/2026An advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER154409.0000000FOR154409.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Election of Class II Directors: Jennifer L. DavisDIRECTOR ELECTIONSISSUER1469198.0000000AGAINST1469198.000000AGAINSTS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Election of Class II Directors: Melody B. MeyerDIRECTOR ELECTIONSISSUER1469198.0000000AGAINST1469198.000000AGAINSTS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Election of Class II Directors: Robert A. MichaelDIRECTOR ELECTIONSISSUER1469198.0000000FOR1469198.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Election of Class II Directors: Frederick H. WaddellDIRECTOR ELECTIONSISSUER1469198.0000000AGAINST1469198.000000AGAINSTS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2026AUDIT-RELATEDISSUER1469198.0000000FOR1469198.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Say on Pay - An advisory vote on the approval of executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER1469198.0000000FOR1469198.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority votingCORPORATE GOVERNANCEISSUER1469198.0000000FOR1469198.000000FORS000002088AbbVie Inc.00287Y109US00287Y109105/08/2026Stockholder Proposal - to Adopt a Policy to Require an Independent ChairCORPORATE GOVERNANCESECURITY HOLDER1469198.0000000AGAINST1469198.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Treatment of LossesCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New TransactionsCORPORATE GOVERNANCEISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Reelect Sylvie Gregoire as DirectorDIRECTOR ELECTIONSISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Reelect June Lee as DirectorDIRECTOR ELECTIONSISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Reelect Troy Ignelzi as DirectorDIRECTOR ELECTIONSISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Compensation ReportCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Compensation of Sylvie Gregoire, Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTESISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Compensation of Marc de Garidel, CEOSECTION 14A SAY-ON-PAY VOTESISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Compensation Report of Corporate OfficersCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Remuneration Policy of Chairwoman of the BoardCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Remuneration Policy of CEOCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Remuneration Policy of DirectorsCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 750,000CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 750,000CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 750,000CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Issuance of Equity or Equity-Linked Securities for Qualified Investors, up to Aggregate Nominal Amount of EUR 237,873.56CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries in the Framework of an Equity Line on the American Market, up to Aggregate Nominal Amount of EUR 20,000CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 237,873.56CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote AboveCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Capitalization of Reserves of Up to EUR 750,000 for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Capital Increase of up to 20 Percent of Issued Capital for Contributions in KindCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Capital Increase of Up to EUR 750,000 for Future Exchange OffersCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 17-22 and 25-26 at EUR 750,000CAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize up to 10 Percent of Issued Capital for Use in Stock Option PlansCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Approve Issuance of Warrants (Bons) Reserved for Services Providers, Consultants, Employees and Executives, up to 10 Percent of Issued Share CapitalCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 28-30, at 10 Percent of Issued CapitalCAPITAL STRUCTUREISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER427254.0000000FOR427254.000000FORS000002088Abivax SA00370M103US00370M103605/11/2026Authorize Filing of Required Documents/Other FormalitiesCORPORATE GOVERNANCEISSUER427254.0000000FOR427254.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Financial Statements and Discharge DirectorsCAPITAL STRUCTURECORPORATE GOVERNANCEISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Treatment of LossesCAPITAL STRUCTUREISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Auditors' Special Report on Related-Party TransactionsCORPORATE GOVERNANCEISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Reelect Julien Miara as DirectorDIRECTOR ELECTIONSISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Reelect Redmile Group as DirectorDIRECTOR ELECTIONSISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Reelect Federico Mingozzi as DirectorDIRECTOR ELECTIONSISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Renew Appointment of Florian Reinaud as CensorCORPORATE GOVERNANCEISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Remuneration of Directors in the Aggregate Amount of EUR 750,000COMPENSATIONISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Stock SplitCAPITAL STRUCTUREISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Reverse Stock SplitCAPITAL STRUCTUREISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Issuance of Equity or Equity-Linked Securities for Private Placements, up to Aggregate Nominal Amount of EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries, up to Aggregate Nominal Amount of EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Issuance of Equity or Equity-Linked Securities in Favor of a Category of Beneficiaries, up to Aggregate Nominal Amount of EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Designated Beneficiaries, up to Aggregate Nominal Amount of EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Capitalization of Reserves of Up to EUR 50 Million for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote AboveCAPITAL STRUCTUREISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 14-19 at EUR 50 MillionCAPITAL STRUCTUREISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Approve Issuance of 67 Million Warrants (BSA 2026) without Preemptive Rights Reserved for Specific BeneficiariesCOMPENSATIONISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize up to 67 Million Shares for Use in Stock Option PlansCOMPENSATIONISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize up to 10 Percent of Issued Capital for Use in Restricted Stock PlansCOMPENSATIONISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 23-25 at 67 Million SharesCOMPENSATIONISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER17584667.0000000FOR17584667.000000FORS000002088Sensorion SAF8312Z102FR001259646805/11/2026Amend Articles of Bylaws to Incorporate Legal ChangesCORPORATE GOVERNANCEISSUER17584667.0000000AGAINST17584667.000000AGAINSTS000002088Sensorion SAF8312Z102FR001259646805/11/2026Authorize Filing of Required Documents/Other FormalitiesCORPORATE GOVERNANCEISSUER17584667.0000000FOR17584667.000000FORS000002088Alto Neuroscience, Inc.02157Q109US02157Q109405/12/2026To elect the Board's Class II Director nominees, Raymond Sanchez, M.D. and Gwill York, to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Raymond Sanchez, M.D.DIRECTOR ELECTIONSISSUER248667.0000000FOR248667.000000FORS000002088Alto Neuroscience, Inc.02157Q109US02157Q109405/12/2026To elect the Board's Class II Director nominees, Raymond Sanchez, M.D. and Gwill York, to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Gwill YorkDIRECTOR ELECTIONSISSUER248667.0000000WITHHOLD248667.000000AGAINSTS000002088Alto Neuroscience, Inc.02157Q109US02157Q109405/12/2026To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026.AUDIT-RELATEDISSUER248667.0000000FOR248667.000000FORS000002088Alto Neuroscience, Inc.02157Q109US02157Q109405/12/2026To approve an amendment and restatement of the Company's 2024 Equity Incentive Plan to treat outstanding pre-funded warrants the same as outstanding shares of Common Stock for purposes of calculating the number of shares to be automatically added to the share reserve thereunder pursuant to the "evergreen" feature of the 2024 Equity Incentive Plan.COMPENSATIONISSUER248667.0000000AGAINST248667.000000AGAINSTS000002088Alto Neuroscience, Inc.02157Q109US02157Q109405/12/2026To approve an amendment and restatement of the Company's 2024 Employee Stock Purchase Plan to treat outstanding pre-funded warrants the same as outstanding shares of Common Stock for purposes of calculating the number of shares to be automatically added to the share reserve thereunder pursuant to the "evergreen" feature of the 2024 Employee Stock Purchase Plan.COMPENSATIONISSUER248667.0000000AGAINST248667.000000AGAINSTS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Jessica L. BlumeDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Kenneth A. BurdickDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Christopher J. CoughlinDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: H. James DallasDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Frederick H. EppingerDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Monte E. FordDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Sarah M. LondonDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Theodore R. SamuelsDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ELECTION OF DIRECTORS: Kenneth Y. TanjiDIRECTOR ELECTIONSISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTESISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.AUDIT-RELATEDISSUER533708.0000000FOR533708.000000FORS000002088Centene Corporation15135B101US15135B101705/12/2026STOCKHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN.CORPORATE GOVERNANCESECURITY HOLDER533708.0000000AGAINST533708.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Election of Directors (Proposal One): Daniel M. JuniusDIRECTOR ELECTIONSISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Election of Directors (Proposal One): Lawrence D. KingsleyDIRECTOR ELECTIONSISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Election of Directors (Proposal One): Sophie V. Vandebroek, PhDDIRECTOR ELECTIONSISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year (Proposal Two).AUDIT-RELATEDISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three).SECTION 14A SAY-ON-PAY VOTESISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Amend Certificate of Incorporation to Declassify the Board (Proposal Four).SHAREHOLDER RIGHTS AND DEFENSESISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Amend Certificate of Incorporation to Provide Shareholders Owning 25% of the Shares of our Capital Stock the Right to Have IDEXX Call a Special Meeting (Proposal Five).CORPORATE GOVERNANCEISSUER61954.0000000FOR61954.000000FORS000002088IDEXX Laboratories, Inc.45168D104US45168D104605/12/2026Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six).CORPORATE GOVERNANCESECURITY HOLDER61954.0000000AGAINST61954.000000FORS000002088Elevance Health, Inc.036752103US036752103805/13/2026Election of Directors: Gail K. BoudreauxDIRECTOR ELECTIONSISSUER246294.0000000FOR246294.000000FORS000002088Elevance Health, Inc.036752103US036752103805/13/2026Election of Directors: Robert L. Dixon, Jr.DIRECTOR ELECTIONSISSUER246294.0000000FOR246294.000000FORS000002088Elevance Health, Inc.036752103US036752103805/13/2026Election of Directors: Deanna D. StrableDIRECTOR ELECTIONSISSUER246294.0000000FOR246294.000000FORS000002088Elevance Health, Inc.036752103US036752103805/13/2026Advisory Vote to Approve the Compensation of Our Named Executive Officers ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER246294.0000000FOR246294.000000FORS000002088Elevance Health, Inc.036752103US036752103805/13/2026Ratification of Ernst & Young LLP as Auditors for 2026.AUDIT-RELATEDISSUER246294.0000000FOR246294.000000FORS000002088Elevance Health, Inc.036752103US036752103805/13/2026Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups.OTHER SOCIAL ISSUESSECURITY HOLDER246294.0000000AGAINST246294.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2026Election of two Class II directors, Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D. to serve until the 2029 Annual Meeting of Shareholders: Elizabeth McKee AndersonDIRECTOR ELECTIONSISSUER784325.0000000WITHHOLD784325.000000AGAINSTS000002088Insmed Incorporated457669307US457669307505/13/2026Election of two Class II directors, Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D. to serve until the 2029 Annual Meeting of Shareholders: Clarissa Desjardins, Ph.D.DIRECTOR ELECTIONSISSUER784325.0000000WITHHOLD784325.000000AGAINSTS000002088Insmed Incorporated457669307US457669307505/13/2026An advisory vote on the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER784325.0000000FOR784325.000000FORS000002088Insmed Incorporated457669307US457669307505/13/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER784325.0000000FOR784325.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Sangeeta BhatiaDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Lloyd CarneyDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Alan GarberDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Reshma KewalramaniDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Michel LagardeDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Jeffrey LeidenDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Diana McKenzieDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Bruce SachsDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Jennifer SchneiderDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Election of Directors: Nancy ThornberryDIRECTOR ELECTIONSISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Approval of 2026 Stock and Option Plan.COMPENSATIONISSUER596178.0000000FOR596178.000000FORS000002088Vertex Pharmaceuticals Incorporated92532F100US92532F100305/13/2026Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.CORPORATE GOVERNANCESECURITY HOLDER596178.0000000AGAINST596178.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Richard E. BullerDIRECTOR ELECTIONSISSUER535389.0000000WITHHOLD535389.000000AGAINSTS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: David F. DalveyDIRECTOR ELECTIONSISSUER535389.0000000WITHHOLD535389.000000AGAINSTS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Leo T. FurchtDIRECTOR ELECTIONSISSUER535389.0000000WITHHOLD535389.000000AGAINSTS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Lance G. LaingDIRECTOR ELECTIONSISSUER535389.0000000FOR535389.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Polly A. MurphyDIRECTOR ELECTIONSISSUER535389.0000000WITHHOLD535389.000000AGAINSTS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Richard J. NigonDIRECTOR ELECTIONSISSUER535389.0000000FOR535389.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Charles R. RompDIRECTOR ELECTIONSISSUER535389.0000000FOR535389.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026Elect eight directors: Brian F. SullivanDIRECTOR ELECTIONSISSUER535389.0000000FOR535389.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026To ratify the appointment of Boulay PLLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER535389.0000000FOR535389.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026To approve, on an advisory basis, named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER535389.0000000FOR535389.000000FORS000002088Celcuity Inc.15102K100US15102K100705/14/2026To approve the Celcuity Inc. 2026 Stock Incentive Plan.COMPENSATIONISSUER535389.0000000AGAINST535389.000000AGAINSTS000002088Celcuity Inc.15102K100US15102K100705/14/2026To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan.COMPENSATIONISSUER535389.0000000FOR535389.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Fernando AguirreDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Jeffrey R. Balser, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: C. David Brown IIDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Alecia A. DeCoudreauxDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Anne M. FinucaneDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: John E. GallinaDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: J. David JoynerDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: J. Scott KirbyDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Michael F. MahoneyDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Leslie V. NorwalkDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Larry M. RobbinsDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Guy P. SansoneDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Election of Directors: Douglas H. ShulmanDIRECTOR ELECTIONSISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Ratification of the Appointment of Our Independent Registered Public Accounting Firm for 2026.AUDIT-RELATEDISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company's Executive Compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Proposal to Approve the Company's 2026 Incentive Compensation Plan.COMPENSATIONISSUER1321167.0000000FOR1321167.000000FORS000002088CVS Health Corporation126650100US126650100605/14/2026Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent.CORPORATE GOVERNANCESECURITY HOLDER1321167.0000000AGAINST1321167.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Olivier LoeillotDIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Karen A. DawesDIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Nicolas M. BarthelemyDIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Carrie Eglinton MannerDIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Konstantin Konstantinov, Ph.D.DIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Martin D. Madaus, D.V.M., Ph.D.DIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Rohin Mhatre, Ph.D.DIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Glenn P. MuirDIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Election of Directors: Margaret A. PaxDIRECTOR ELECTIONSISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Ratification of the selection of Ernst & Young LLP as Repligen Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER109629.0000000FOR109629.000000FORS000002088Repligen Corporation759916109US759916109505/14/2026Advisory vote to approve the compensation paid to Repligen Corporation's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER109629.0000000FOR109629.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Nominees: Emil D. Kakkis, M.D., Ph.D.DIRECTOR ELECTIONSISSUER162009.0000000FOR162009.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Nominees: Shehnaaz Suliman, M.D.DIRECTOR ELECTIONSISSUER162009.0000000FOR162009.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Nominees: Daniel G. WelchDIRECTOR ELECTIONSISSUER162009.0000000FOR162009.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Approval of the Third Amended and Restated 2023 Incentive Plan.COMPENSATIONISSUER162009.0000000FOR162009.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER162009.0000000FOR162009.000000FORS000002088Ultragenyx Pharmaceutical Inc.90400D108US90400D108105/14/2026Advisory (non-binding) vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER162009.0000000FOR162009.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/15/2026Election of Class III Directors: Krish S. KrishnanDIRECTOR ELECTIONSISSUER275709.0000000FOR275709.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/15/2026Election of Class III Directors: Christopher MasonDIRECTOR ELECTIONSISSUER275709.0000000FOR275709.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/15/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER275709.0000000FOR275709.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/15/2026Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.SECTION 14A SAY-ON-PAY VOTESISSUER275709.0000000FOR275709.000000FORS000002088Krystal Biotech, Inc.501147102US501147102705/15/2026Approval of the Company's Non-Employee Director Compensation Policy.COMPENSATIONISSUER275709.0000000FOR275709.000000FORS000002088Nurix Therapeutics, Inc.67080M103US67080M103605/15/2026Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1189260.0000000FOR1189260.000000FORS000002088Nurix Therapeutics, Inc.67080M103US67080M103605/15/2026Election of Class III Directors: Roger Dansey, M.D.DIRECTOR ELECTIONSISSUER1189260.0000000FOR1189260.000000FORS000002088Nurix Therapeutics, Inc.67080M103US67080M103605/15/2026Election of Class III Directors: Paul M. SilvaDIRECTOR ELECTIONSISSUER1189260.0000000FOR1189260.000000FORS000002088Nurix Therapeutics, Inc.67080M103US67080M103605/15/2026Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2026.AUDIT-RELATEDISSUER1189260.0000000FOR1189260.000000FORS000002088Nurix Therapeutics, Inc.67080M103US67080M103605/15/2026To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1189260.0000000FOR1189260.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: W. Don CornwellDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Frank D'AmelioDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: JoEllen Lyons DillonDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Elisha FinneyDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Leo GroothuisDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Melina HigginsDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: James M. KiltsDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Richard MarkDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Mark ParrishDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Michael SeverinoDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: David SimmonsDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Scott A. SmithDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: Rogerio Vivaldi CoelhoDIRECTOR ELECTIONSISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Approval of, on a non-binding advisory basis, the 2025 compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER934905.0000000FOR934905.000000FORS000002088Viatris Inc.92556V106US92556V106105/15/2026Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER934905.0000000FOR934905.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. AustinDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. BradwayDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. DrakeDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. DrukerDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. EckertDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. GarlandDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.DIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar IshrakDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler JacksDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. KlotmanDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. KullmanDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. MilesDIRECTOR ELECTIONSISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER306230.0000000FOR306230.000000FORS000002088Amgen Inc.031162100US031162100905/19/2026Stockholder proposal to require an independent board chairman.CORPORATE GOVERNANCESECURITY HOLDER306230.0000000AGAINST306230.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/20/2026To elect the following nominees as Class I directors of Alnylam: Stuart A. ArbuckleDIRECTOR ELECTIONSISSUER529847.0000000FOR529847.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/20/2026To elect the following nominees as Class I directors of Alnylam: Yvonne L. Greenstreet, M.D.DIRECTOR ELECTIONSISSUER529847.0000000FOR529847.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/20/2026To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.DIRECTOR ELECTIONSISSUER529847.0000000AGAINST529847.000000AGAINSTS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/20/2026To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER529847.0000000FOR529847.000000FORS000002088Alnylam Pharmaceuticals, Inc.02043Q107US02043Q107605/20/2026To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER529847.0000000FOR529847.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Peter Fong, Ph.D.DIRECTOR ELECTIONSISSUER468469.0000000WITHHOLD468469.000000AGAINSTS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten BoessDIRECTOR ELECTIONSISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.DIRECTOR ELECTIONSISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.DIRECTOR ELECTIONSISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.DIRECTOR ELECTIONSISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. SouthwellDIRECTOR ELECTIONSISSUER468469.0000000WITHHOLD468469.000000AGAINSTS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.DIRECTOR ELECTIONSISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The ratification of the appointment of Eisner Amper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026A non-binding, advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER468469.0000000FOR468469.000000FORS000002088Rocket Pharmaceuticals, Inc.77313F106US77313F106605/20/2026The approval of the proposed stock option exchange program; andCOMPENSATIONISSUER468469.0000000AGAINST468469.000000AGAINSTS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Marc N. CasperDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Nelson J. ChaiDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Ruby R. ChandyDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: C. Martin HarrisDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Tyler JacksDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Jennifer M. JohnsonDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: R. Alexandra KeithDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Karen S. LynchDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Debora L. SparDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Scott M. SperlingDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Election of Directors: Dion J. WeislerDIRECTOR ELECTIONSISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER919391.0000000FOR919391.000000FORS000002088Thermo Fisher Scientific Inc.883556102US883556102305/20/2026Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2026.AUDIT-RELATEDISSUER919391.0000000FOR919391.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Paul M. BisaroDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Vanessa BroadhurstDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Frank A. D'AmelioDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Gavin D.K. HattersleyDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Sanjay KhoslaDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Antoinette R. LeatherberryDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Michael B. McCallisterDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Gregory NordenDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Kristin C. PeckDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Willie M. ReedDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Mark StetterDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Election of Directors: Stephanie TileniusDIRECTOR ELECTIONSISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Advisory vote to approve our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Advisory vote to approve the frequency of future advisory votes on our executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER158414.0000000ONE YEAR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER158414.0000000FOR158414.000000FORS000002088Zoetis Inc.98978V103US98978V103505/20/2026Shareholder proposal to permit shareholder action by written consent.CORPORATE GOVERNANCESECURITY HOLDER158414.0000000AGAINST158414.000000FORS000002088Beta Bionics, Inc.08659B102US08659B102605/21/2026To elect two Class I directors, as nominated by the Board of Directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Sean D. CarneyDIRECTOR ELECTIONSISSUER157871.0000000FOR157871.000000FORS000002088Beta Bionics, Inc.08659B102US08659B102605/21/2026To elect two Class I directors, as nominated by the Board of Directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christy JonesDIRECTOR ELECTIONSISSUER157871.0000000FOR157871.000000FORS000002088Beta Bionics, Inc.08659B102US08659B102605/21/2026To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER157871.0000000FOR157871.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/21/2026Election of Class II directors: Olivia KirtleyDIRECTOR ELECTIONSISSUER2514077.0000000FOR2514077.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/21/2026Election of Class II directors: Max LinDIRECTOR ELECTIONSISSUER2514077.0000000FOR2514077.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/21/2026Election of Class II directors: Steve MillerDIRECTOR ELECTIONSISSUER2514077.0000000FOR2514077.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/21/2026Ratification of the appointment of KPMG LLP as the independent accounting firm for the year ending December 31, 2026AUDIT-RELATEDISSUER2514077.0000000FOR2514077.000000FORS000002088BrightSpring Health Services, Inc.10950A106US10950A106005/21/2026Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER2514077.0000000FOR2514077.000000FORS000002088Dianthus Therapeutics, Inc.252828108US252828108005/21/2026To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Sujay KangoDIRECTOR ELECTIONSISSUER482750.0000000FOR482750.000000FORS000002088Dianthus Therapeutics, Inc.252828108US252828108005/21/2026To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeDIRECTOR ELECTIONSISSUER482750.0000000FOR482750.000000FORS000002088Dianthus Therapeutics, Inc.252828108US252828108005/21/2026To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Jonathan Violin, Ph.D.DIRECTOR ELECTIONSISSUER482750.0000000FOR482750.000000FORS000002088Dianthus Therapeutics, Inc.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER482750.0000000FOR482750.000000FORS000002088Dianthus Therapeutics, Inc.252828108US252828108005/21/2026To ratify the appointment of Deloitte & Touche, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER482750.0000000FOR482750.000000FORS000002088Nuvation Bio Inc.67080N101US67080N101905/21/2026Election of Directors: Robert BazemoreDIRECTOR ELECTIONSISSUER419812.0000000FOR419812.000000FORS000002088Nuvation Bio Inc.67080N101US67080N101905/21/2026Election of Directors: Robert Mashal, M.D.DIRECTOR ELECTIONSISSUER419812.0000000FOR419812.000000FORS000002088Nuvation Bio Inc.67080N101US67080N101905/21/2026Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER419812.0000000FOR419812.000000FORS000002088Nuvation Bio Inc.67080N101US67080N101905/21/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER419812.0000000FOR419812.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/21/2026To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D.DIRECTOR ELECTIONSISSUER1246020.0000000FOR1246020.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/21/2026To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. EnrightDIRECTOR ELECTIONSISSUER1246020.0000000FOR1246020.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/21/2026To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: James R. MeyersDIRECTOR ELECTIONSISSUER1246020.0000000FOR1246020.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/21/2026To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1246020.0000000FOR1246020.000000FORS000002088Vera Therapeutics, Inc.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER1246020.0000000FOR1246020.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Ilya RachmanDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Gabriel MorrisDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Jason HsuDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Magda MarquetDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Helen C. AdamsDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Carey NgDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Jane BuchanDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Yekaterina ChudnovskyDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To elect the nine (9) nominees listed below to serve as members of the Board of Directors of the Company until the next annual meeting of stockholders and until their successors are duly elected and qualified: Nancy ChangDIRECTOR ELECTIONSISSUER326401.0000000FOR326401.000000FORS000002088Immix Biopharma, Inc.45258H106US45258H106805/22/2026To ratify the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER326401.0000000FOR326401.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Douglas M. Baker, Jr.DIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Mary Ellen CoeDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Pamela J. CraigDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Robert M. DavisDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Thomas H. GlocerDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Surendralal L. KarsanbhaiDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Risa J. Lavizzo-Mourey, M.D.DIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Stephen L. Mayo, Ph.D.DIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Paul B. Rothman, M.D.DIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Patricia F. RussoDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Christine E. Seidman, M.D.DIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Inge G. ThulinDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Election of Directors: Kathy J. WardenDIRECTOR ELECTIONSISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Non-binding advisory vote to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Ratification of the appointment of the Company's independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER3124221.0000000FOR3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on DEI risks in federal contracting.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER3124221.0000000AGAINST3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on healthcare coverage gaps.ENVIRONMENT OR CLIMATEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESSECURITY HOLDER3124221.0000000AGAINST3124221.000000FORS000002088Merck & Co., Inc.58933Y105US58933Y105505/26/2026Shareholder proposal regarding a report on political contributions.OTHER SOCIAL ISSUESSECURITY HOLDER3124221.0000000AGAINST3124221.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.DIRECTOR ELECTIONSISSUER663136.0000000WITHHOLD663136.000000AGAINSTS000002088Cytokinetics, Incorporated23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D.DIRECTOR ELECTIONSISSUER663136.0000000WITHHOLD663136.000000AGAINSTS000002088Cytokinetics, Incorporated23282W605US23282W605705/27/2026Election of Class I Directors for terms expiring in 2029: Nancy J. WysenskiDIRECTOR ELECTIONSISSUER663136.0000000WITHHOLD663136.000000AGAINSTS000002088Cytokinetics, Incorporated23282W605US23282W605705/27/2026To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance thereunder by 1,000,000 shares of common stock.COMPENSATIONISSUER663136.0000000FOR663136.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/27/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER663136.0000000FOR663136.000000FORS000002088Cytokinetics, Incorporated23282W605US23282W605705/27/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER663136.0000000FOR663136.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To re-appoint Siddharth Kaul as a director who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To re-appoint William Pao, M.D., Ph.D. as a director who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To re-appoint Kristine Peterson as a director who retires in accordance with the articles of association.DIRECTOR ELECTIONSISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To ratify the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting firm for the year ending 31 December 2026.AUDIT-RELATEDISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To re-appoint Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of our next annual general meeting of shareholders.AUDIT-RELATEDISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To authorize the audit committee to determine the U.K. statutory auditors' remuneration for the year ending 31 December 2026.AUDIT-RELATEDISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To receive and adopt the U.K. statutory annual accounts and reports for the year ended 31 December 2025.CORPORATE GOVERNANCEISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the attached proxy statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors' remuneration policy set out on 26 to 56 2025 U.K. Annual Report (excluding the directors' remuneration policy set out on A7 to A18 of Annex A).COMPENSATIONISSUER715068.0000000FOR715068.000000FORS000002088Immunocore Holdings Plc45258D105US45258D105405/27/2026To authorize the Company to make political donations/incur political expenditure.OTHER SOCIAL ISSUESISSUER715068.0000000FOR715068.000000FORS000002088Kyverna Therapeutics, Inc.501976104US501976104905/27/2026The election of two Class II directors to hold office until the Company's 2029 annual meeting of stockholders: Ian ClarkDIRECTOR ELECTIONSISSUER1142161.0000000FOR1142161.000000FORS000002088Kyverna Therapeutics, Inc.501976104US501976104905/27/2026The election of two Class II directors to hold office until the Company's 2029 annual meeting of stockholders: Christi ShawDIRECTOR ELECTIONSISSUER1142161.0000000FOR1142161.000000FORS000002088Kyverna Therapeutics, Inc.501976104US501976104905/27/2026The ratification of the appointment by the Audit Committee of the Company's Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm and independent auditor for the year ending December 31, 2026.AUDIT-RELATEDISSUER1142161.0000000FOR1142161.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/27/2026Election of Class I Directors for terms expiring in 2029: Mark McKennaDIRECTOR ELECTIONSISSUER897045.0000000FOR897045.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/27/2026Election of Class I Directors for terms expiring in 2029: Cameron Turtle, D.Phil.DIRECTOR ELECTIONSISSUER897045.0000000FOR897045.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/27/2026Election of Class I Directors for terms expiring in 2029: Laurie StelzerDIRECTOR ELECTIONSISSUER897045.0000000FOR897045.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER897045.0000000FOR897045.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/27/2026To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER897045.0000000FOR897045.000000FORS000002088Spyre Therapeutics, Inc.00773J202US00773J202405/27/2026To approve the Company's amended and restated 2016 Employee Stock Purchase Plan.COMPENSATIONISSUER897045.0000000FOR897045.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Saumya SutariaDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: J. Robert KerreyDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Vineeta AgarwalaDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: James L. BiermanDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Roy BluntDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Richard W. FisherDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Meghan M. FitzGeraldDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Cecil D. HaneyDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Christopher S. LynchDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Richard J. MarkDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Tammy RomoDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director's earlier resignation or removal: Nadja Y. WestDIRECTOR ELECTIONSISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To vote, on an advisory basis, to approve the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER574402.0000000FOR574402.000000FORS000002088Tenet Healthcare Corporation88033G407US88033G407305/27/2026To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2026.AUDIT-RELATEDISSUER574402.0000000FOR574402.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To elect the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Taylor Schreiber, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1295414.0000000FOR1295414.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To elect the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Helen M. BoudreauDIRECTOR ELECTIONSISSUER1295414.0000000FOR1295414.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To elect the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Clay Siegall, Ph.D.DIRECTOR ELECTIONSISSUER1295414.0000000FOR1295414.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER1295414.0000000FOR1295414.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1295414.0000000FOR1295414.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To conduct an advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1295414.0000000ONE YEAR1295414.000000FORS000002088Shattuck Labs, Inc.82024L103US82024L103505/28/2026To approve an amendment and restatement of the Company's 2020 Equity Incentive Plan.COMPENSATIONISSUER1295414.0000000AGAINST1295414.000000AGAINSTS000002088Tyra Biosciences, Inc.90240B106US90240B106105/28/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Habib J. DableDIRECTOR ELECTIONSISSUER291152.0000000FOR291152.000000FORS000002088Tyra Biosciences, Inc.90240B106US90240B106105/28/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Susan Moran, M.D., M.S.C.E.DIRECTOR ELECTIONSISSUER291152.0000000FOR291152.000000FORS000002088Tyra Biosciences, Inc.90240B106US90240B106105/28/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Robert MoreDIRECTOR ELECTIONSISSUER291152.0000000FOR291152.000000FORS000002088Tyra Biosciences, Inc.90240B106US90240B106105/28/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER291152.0000000FOR291152.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Charles BakerDIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Timothy FlynnDIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Paul GarciaDIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Kristen GilDIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Scott Gottlieb, M.D.DIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Stephen HemsleyDIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: F. William McNabb IIIDIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: Valerie Montgomery Rice, M.D.DIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Election of Directors: John Noseworthy, M.D.DIRECTOR ELECTIONSISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2026.AUDIT-RELATEDISSUER1254745.0000000FOR1254745.000000FORS000002088UnitedHealth Group Incorporated91324P102US91324P102106/01/2026If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent.CORPORATE GOVERNANCESECURITY HOLDER1254745.0000000AGAINST1254745.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Elizabeth M. AndersonDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Barbara W. BodemDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Ian T. ClarkDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Athena CountouriotisDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Willard DereDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Mark J. EnyedyDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Alexander HardyDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Maykin HoDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Robert J. HombachDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026Election of Directors: Timothy P. WalbertDIRECTOR ELECTIONSISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER58700.0000000FOR58700.000000FORS000002088BioMarin Pharmaceutical Inc.09061G101US09061G101306/02/2026To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.COMPENSATIONISSUER58700.0000000FOR58700.000000FORS000002088Crescent Biopharma, Inc.G2545C104KYG2545C104206/02/2026Election of Class II Director for term expiring at the 2029 Annual General Meeting of Shareholders or until their successor is duly elected and qualified or until their earlier death, resignation, disqualification or removal: Susan Moran, M.D., MSCEDIRECTOR ELECTIONSISSUER187920.0000000FOR187920.000000FORS000002088Crescent Biopharma, Inc.G2545C104KYG2545C104206/02/2026To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Crescent Biopharma, Inc. for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER187920.0000000FOR187920.000000FORS000002088Crescent Biopharma, Inc.G2545C104KYG2545C104206/02/2026To approve, on a non-binding, advisory basis, the compensation of Crescent Biopharma, Inc. 's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER187920.0000000FOR187920.000000FORS000002088Crescent Biopharma, Inc.G2545C104KYG2545C104206/02/2026To vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve compensation for Crescent Biopharma, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER187920.0000000ONE YEAR187920.000000FORS000002088Evommune, Inc.30054Y107US30054Y107306/02/2026To elect two nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders: Luis PenaDIRECTOR ELECTIONSISSUER221236.0000000WITHHOLD221236.000000AGAINSTS000002088Evommune, Inc.30054Y107US30054Y107306/02/2026To elect two nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders: Eugene A. BauerDIRECTOR ELECTIONSISSUER221236.0000000FOR221236.000000FORS000002088Evommune, Inc.30054Y107US30054Y107306/02/2026To ratify the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER221236.0000000FOR221236.000000FORS000002088Kodiak Sciences Inc.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement: Charles A. BancroftDIRECTOR ELECTIONSISSUER1005611.0000000FOR1005611.000000FORS000002088Kodiak Sciences Inc.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement: Bassil I. Dahiyat, Ph.D.DIRECTOR ELECTIONSISSUER1005611.0000000FOR1005611.000000FORS000002088Kodiak Sciences Inc.50015M109US50015M109906/02/2026Elect three Class II directors nominated by our board and named in this proxy statement: Taiyin Yang, Ph.D.DIRECTOR ELECTIONSISSUER1005611.0000000FOR1005611.000000FORS000002088Kodiak Sciences Inc.50015M109US50015M109906/02/2026Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1005611.0000000FOR1005611.000000FORS000002088Kodiak Sciences Inc.50015M109US50015M109906/02/2026Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER1005611.0000000FOR1005611.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2026Election of Class II Directors for terms expiring in 2029: Lawrence KleinDIRECTOR ELECTIONSISSUER276109.0000000FOR276109.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2026Election of Class II Directors for terms expiring in 2029: Chris MartinDIRECTOR ELECTIONSISSUER276109.0000000FOR276109.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2026To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Oruka Therapeutics, Inc. for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER276109.0000000FOR276109.000000FORS000002088Oruka Therapeutics, Inc.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER276109.0000000FOR276109.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: June Almenoff, MD, PhDDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: Michael Davidson, MDDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: Declan Doogan, MDDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: Christopher T. GiordanoDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: Robyn M. HunterDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: Gerald T. ProehlDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Election of Directors: Stuart Rich, MDDIRECTOR ELECTIONSISSUER2492376.0000000FOR2492376.000000FORS000002088Tenax Therapeutics, Inc.88032L605US88032L605606/02/2026Ratification of the appointment of Cherry Bekaert LLP as the independent registered public accounting firm of Tenax Therapeutics, Inc. for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2492376.0000000FOR2492376.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/02/2026To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Tomas KiselakDIRECTOR ELECTIONSISSUER309118.0000000FOR309118.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/02/2026To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Jennifer K. MosesDIRECTOR ELECTIONSISSUER309118.0000000FOR309118.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/02/2026To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER309118.0000000FOR309118.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/02/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER309118.0000000FOR309118.000000FORS000002088Viridian Therapeutics, Inc.92790C104US92790C104506/02/2026To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER309118.0000000ONE YEAR309118.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn SvoronosDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian CannonDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven GannonDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth GarofaloDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin GoverDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick MachadoDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian MortimerDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary PatouDIRECTOR ELECTIONSISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve, on an advisory basis, the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve, on an advisory basis, the frequency of future shareholder advisory votes to approve the compensation of the Corporation's named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER58000.0000000ONE YEAR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To approve the Corporation's 2026 Equity Incentive Plan;COMPENSATIONISSUER58000.0000000AGAINST58000.000000AGAINSTS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To appoint PricewaterhouseCoopers LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation;AUDIT-RELATEDISSUER58000.0000000FOR58000.000000FORS000002088Xenon Pharmaceuticals Inc.98420N105CA98420N105006/02/2026To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation; andAUDIT-RELATEDISSUER58000.0000000FOR58000.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John EvansDIRECTOR ELECTIONSISSUER1097392.0000000FOR1097392.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER1097392.0000000FOR1097392.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/03/2026Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029: Christi ShawDIRECTOR ELECTIONSISSUER1097392.0000000FOR1097392.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/03/2026Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1097392.0000000FOR1097392.000000FORS000002088Beam Therapeutics Inc.07373V105US07373V105206/03/2026Approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1097392.0000000FOR1097392.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2026ELECTION OF DIRECTORS: Jennifer CookDIRECTOR ELECTIONSISSUER397945.0000000FOR397945.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2026ELECTION OF DIRECTORS: David Schenkein, M.D.DIRECTOR ELECTIONSISSUER397945.0000000FOR397945.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2026ELECTION OF DIRECTORS: Ryan Watts, Ph.D.DIRECTOR ELECTIONSISSUER397945.0000000FOR397945.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER397945.0000000FOR397945.000000FORS000002088Denali Therapeutics Inc.24823R105US24823R105906/03/2026Advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER397945.0000000FOR397945.000000FORS000002088Stoke Therapeutics, Inc.86150R107US86150R107706/03/2026Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: G. Clare Kahn, Ph.D.DIRECTOR ELECTIONSISSUER418934.0000000FOR418934.000000FORS000002088Stoke Therapeutics, Inc.86150R107US86150R107706/03/2026Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D.DIRECTOR ELECTIONSISSUER418934.0000000FOR418934.000000FORS000002088Stoke Therapeutics, Inc.86150R107US86150R107706/03/2026Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne SmithDIRECTOR ELECTIONSISSUER418934.0000000FOR418934.000000FORS000002088Stoke Therapeutics, Inc.86150R107US86150R107706/03/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER418934.0000000FOR418934.000000FORS000002088Stoke Therapeutics, Inc.86150R107US86150R107706/03/2026To approve, on an advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER418934.0000000FOR418934.000000FORS000002088Alignment Healthcare, Inc.01625V104US01625V104406/04/2026Election of Directors: Jody BilneyDIRECTOR ELECTIONSISSUER1414085.0000000WITHHOLD1414085.000000AGAINSTS000002088Alignment Healthcare, Inc.01625V104US01625V104406/04/2026Election of Directors: David HodgsonDIRECTOR ELECTIONSISSUER1414085.0000000WITHHOLD1414085.000000AGAINSTS000002088Alignment Healthcare, Inc.01625V104US01625V104406/04/2026Election of Directors: Jacqueline KosecoffDIRECTOR ELECTIONSISSUER1414085.0000000WITHHOLD1414085.000000AGAINSTS000002088Alignment Healthcare, Inc.01625V104US01625V104406/04/2026Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2026AUDIT-RELATEDISSUER1414085.0000000FOR1414085.000000FORS000002088Alignment Healthcare, Inc.01625V104US01625V104406/04/2026Approval, on an non-binding, advisory basis, of the compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTESISSUER1414085.0000000FOR1414085.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: David Dean HalbertDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Brian J. BrilleDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Peter M. CastlemanDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: David FredericksonDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Joseph E. GilliamDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Jon S. HalbertDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Laura I. JohansenDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Lloyd B. Minor, M.D.DIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Danny PhillipsDIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026Election of Directors: Jeffrey Vacirca, M.D.DIRECTOR ELECTIONSISSUER1916767.0000000FOR1916767.000000FORS000002088Caris Life Sciences, Inc.142152107US142152107106/04/2026To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1916767.0000000FOR1916767.000000FORS000002088CG Oncology, Inc.156944100US156944100906/04/2026To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christina RossiDIRECTOR ELECTIONSISSUER1153973.0000000FOR1153973.000000FORS000002088CG Oncology, Inc.156944100US156944100906/04/2026To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Victor Tong, Jr.DIRECTOR ELECTIONSISSUER1153973.0000000FOR1153973.000000FORS000002088CG Oncology, Inc.156944100US156944100906/04/2026To ratify the appointment by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1153973.0000000FOR1153973.000000FORS000002088CG Oncology, Inc.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER1153973.0000000FOR1153973.000000FORS000002088CG Oncology, Inc.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER1153973.0000000ONE YEAR1153973.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/04/2026Election of Directors: Spencer R. BerthelsenDIRECTOR ELECTIONSISSUER882823.0000000AGAINST882823.000000AGAINSTS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/04/2026Election of Directors: Joan E. HermanDIRECTOR ELECTIONSISSUER882823.0000000AGAINST882823.000000AGAINSTS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/04/2026To make an advisory vote on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER882823.0000000FOR882823.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/04/2026To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.COMPENSATIONISSUER882823.0000000FOR882823.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/04/2026To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan.COMPENSATIONISSUER882823.0000000FOR882823.000000FORS000002088Ionis Pharmaceuticals, Inc.462222100US462222100406/04/2026To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year.AUDIT-RELATEDISSUER882823.0000000FOR882823.000000FORS000002088MBX Biosciences, Inc.55287L101US55287L101706/04/2026Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Patrick J. HeronDIRECTOR ELECTIONSISSUER690209.0000000FOR690209.000000FORS000002088MBX Biosciences, Inc.55287L101US55287L101706/04/2026Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersDIRECTOR ELECTIONSISSUER690209.0000000FOR690209.000000FORS000002088MBX Biosciences, Inc.55287L101US55287L101706/04/2026Ratification of the appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2026.AUDIT-RELATEDISSUER690209.0000000FOR690209.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/04/2026Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified: Spike LoyDIRECTOR ELECTIONSISSUER939229.0000000FOR939229.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/04/2026Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER939229.0000000FOR939229.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/04/2026Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER939229.0000000FOR939229.000000FORS000002088MoonLake Immunotherapeutics61559X104KY61559X104506/04/2026Approval of an amendment and restatement of the Company's 2022 Equity Incentive Plan.COMPENSATIONISSUER939229.0000000FOR939229.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Pablo LegorretaDIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Ted Love, M.D.DIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Bonnie Bassler, Ph.D.DIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Vlad Coric, M.D.DIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Catherine EngelbertDIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Carole Ho, M.D.DIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: David HodgsonDIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Gregory NordenDIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Election of Directors: Elizabeth WeathermanDIRECTOR ELECTIONSISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026A non-binding advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.AUDIT-RELATEDISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2025.CORPORATE GOVERNANCEISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Approve on a non-binding advisory basis our U.K. directors' remuneration report for the fiscal year ended December 31, 2025.COMPENSATIONISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.AUDIT-RELATEDISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.AUDIT-RELATEDISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Approve the terms of the agreements and counterparties pursuant to which we may purchase our Class A ordinary shares.CAPITAL STRUCTUREISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Authorize the Board to allot shares.CAPITAL STRUCTUREISSUER1241743.0000000FOR1241743.000000FORS000002088Royalty Pharma plcG7709Q104GB00BMVP7Y0906/04/2026Authorize the Board to allot shares without rights of pre-emption (special resolution).CAPITAL STRUCTUREISSUER1241743.0000000FOR1241743.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/04/2026To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: David HallalDIRECTOR ELECTIONSISSUER1499080.0000000FOR1499080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/04/2026To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kristina BurowDIRECTOR ELECTIONSISSUER1499080.0000000FOR1499080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/04/2026To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Michael GilmanDIRECTOR ELECTIONSISSUER1499080.0000000FOR1499080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/04/2026To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Katie PengDIRECTOR ELECTIONSISSUER1499080.0000000FOR1499080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/04/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1499080.0000000FOR1499080.000000FORS000002088Scholar Rock Holding Corporation80706P103US80706P103006/04/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1499080.0000000AGAINST1499080.000000AGAINSTS000002088Tango Therapeutics, Inc.87583X109US87583X109006/04/2026Election of Class II Directors: Malte Peters, M.D.DIRECTOR ELECTIONSISSUER690986.0000000FOR690986.000000FORS000002088Tango Therapeutics, Inc.87583X109US87583X109006/04/2026Election of Class II Directors: Kanishka PothulaDIRECTOR ELECTIONSISSUER690986.0000000FOR690986.000000FORS000002088Tango Therapeutics, Inc.87583X109US87583X109006/04/2026Election of Class II Directors: Mace Rothenberg, M.D.DIRECTOR ELECTIONSISSUER690986.0000000FOR690986.000000FORS000002088Tango Therapeutics, Inc.87583X109US87583X109006/04/2026To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER690986.0000000FOR690986.000000FORS000002088Tango Therapeutics, Inc.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER690986.0000000FOR690986.000000FORS000002088Axsome Therapeutics, Inc.05464T104US05464T104306/05/2026Election of Directors: Mark SaadDIRECTOR ELECTIONSISSUER151210.0000000WITHHOLD151210.000000AGAINSTS000002088Axsome Therapeutics, Inc.05464T104US05464T104306/05/2026Election of Directors: Susan Mahony, Ph.D., MBADIRECTOR ELECTIONSISSUER151210.0000000WITHHOLD151210.000000AGAINSTS000002088Axsome Therapeutics, Inc.05464T104US05464T104306/05/2026To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER151210.0000000FOR151210.000000FORS000002088Axsome Therapeutics, Inc.05464T104US05464T104306/05/2026To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER151210.0000000FOR151210.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/05/2026The election of two Class II directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his respective successor has been duly elected and qualified: Alexander (Bo) CumboDIRECTOR ELECTIONSISSUER1291599.0000000FOR1291599.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/05/2026The election of two Class II directors, each to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until his respective successor has been duly elected and qualified: Douglas Williams, Ph.D.DIRECTOR ELECTIONSISSUER1291599.0000000FOR1291599.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/05/2026The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER1291599.0000000FOR1291599.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/05/2026The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended, relating to the removal of directors for "cause";SHAREHOLDER RIGHTS AND DEFENSESISSUER1291599.0000000FOR1291599.000000FORS000002088Climb Bio, Inc.28658R106US28658R106806/05/2026The approval of an amendment to our 2021 Equity Incentive Plan to amend the provision providing for an automatic share pool increase to include prefunded warrants in the calculation of the annual increase; andCOMPENSATIONISSUER1291599.0000000AGAINST1291599.000000AGAINSTS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: David LubnerDIRECTOR ELECTIONSISSUER117100.0000000FOR117100.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Brian PosnerDIRECTOR ELECTIONSISSUER117100.0000000FOR117100.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified: Jason RhodesDIRECTOR ELECTIONSISSUER117100.0000000FOR117100.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To vote, on an advisory basis, to approve the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER117100.0000000FOR117100.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares.CAPITAL STRUCTUREISSUER117100.0000000FOR117100.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To approve an amendment to our Restated Certificate of Incorporation to provide for officer exculpation.CORPORATE GOVERNANCEISSUER117100.0000000FOR117100.000000FORS000002088Dyne Therapeutics, Inc.26818M108US26818M108006/05/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER117100.0000000FOR117100.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Julian C. BakerDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques BienaimeDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Otis W. BrawleyDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Paul J. ClancyDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jacqualyn A. FouseDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Edmund P. HarriganDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Katherine A. HighDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: William J. MueryDIRECTOR ELECTIONSISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER290640.0000000FOR290640.000000FORS000002088Incyte Corporation45337C102US45337C102706/08/2026Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER290640.0000000FOR290640.000000FORS000002088Tectonic Therapeutic, Inc.878972108US878972108606/08/2026Election of Directors: Timothy A. Springer, Ph.D.DIRECTOR ELECTIONSISSUER30632.0000000WITHHOLD30632.000000AGAINSTS000002088Tectonic Therapeutic, Inc.878972108US878972108606/08/2026Election of Directors: Stefan Vitorovic, M.S., M.B.A.DIRECTOR ELECTIONSISSUER30632.0000000FOR30632.000000FORS000002088Tectonic Therapeutic, Inc.878972108US878972108606/08/2026Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER30632.0000000FOR30632.000000FORS000002088Tectonic Therapeutic, Inc.878972108US878972108606/08/2026Advisory approval of the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER30632.0000000FOR30632.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/09/2026Election of Class III Directors for terms expiring in 2029: Mark C. McKennaDIRECTOR ELECTIONSISSUER541998.0000000FOR541998.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/09/2026Election of Class III Directors for terms expiring in 2029: Jennifer FoxDIRECTOR ELECTIONSISSUER541998.0000000FOR541998.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/09/2026Election of Class III Directors for terms expiring in 2029: William (BJ) Jones, Jr.DIRECTOR ELECTIONSISSUER541998.0000000FOR541998.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/09/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER541998.0000000FOR541998.000000FORS000002088Apogee Therapeutics, Inc.03770N101US03770N101906/09/2026Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER541998.0000000FOR541998.000000FORS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2026To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Christopher Bowden, M.D.DIRECTOR ELECTIONSISSUER591014.0000000FOR591014.000000FORS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2026To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Carolyn Ng, Ph.D.DIRECTOR ELECTIONSISSUER591014.0000000FOR591014.000000FORS000002088Bicara Therapeutics Inc.055477103US055477103206/09/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER591014.0000000FOR591014.000000FORS000002088Cogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dr. Chris CainDIRECTOR ELECTIONSISSUER357081.0000000FOR357081.000000FORS000002088Cogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Arlene M. MorrisDIRECTOR ELECTIONSISSUER357081.0000000FOR357081.000000FORS000002088Cogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Todd ShegogDIRECTOR ELECTIONSISSUER357081.0000000FOR357081.000000FORS000002088Cogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER357081.0000000FOR357081.000000FORS000002088Cogent Biosciences, Inc.19240Q201US19240Q201206/09/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER357081.0000000FOR357081.000000FORS000002088Enliven Therapeutics, Inc.29337E102US29337E102906/09/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Richard Fair, M.B.A.DIRECTOR ELECTIONSISSUER81263.0000000FOR81263.000000FORS000002088Enliven Therapeutics, Inc.29337E102US29337E102906/09/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Lori Kunkel, M.D.DIRECTOR ELECTIONSISSUER81263.0000000FOR81263.000000FORS000002088Enliven Therapeutics, Inc.29337E102US29337E102906/09/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER81263.0000000FOR81263.000000FORS000002088Enliven Therapeutics, Inc.29337E102US29337E102906/09/2026To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.CAPITAL STRUCTUREISSUER81263.0000000FOR81263.000000FORS000002088Enliven Therapeutics, Inc.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER81263.0000000FOR81263.000000FORS000002088Enliven Therapeutics, Inc.29337E102US29337E102906/09/2026To approve, in an advisory (non-binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER81263.0000000ONE YEAR81263.000000FORS000002088Immunome, Inc.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: James BoylanDIRECTOR ELECTIONSISSUER1666114.0000000FOR1666114.000000FORS000002088Immunome, Inc.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Sandra Swain, M.D.DIRECTOR ELECTIONSISSUER1666114.0000000FOR1666114.000000FORS000002088Immunome, Inc.45257U108US45257U108806/09/2026To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Philip WagenheimDIRECTOR ELECTIONSISSUER1666114.0000000FOR1666114.000000FORS000002088Immunome, Inc.45257U108US45257U108806/09/2026To ratify the appointment of Ernst & Young LLP our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1666114.0000000FOR1666114.000000FORS000002088Immunome, Inc.45257U108US45257U108806/09/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1666114.0000000FOR1666114.000000FORS000002088Immunome, Inc.45257U108US45257U108806/09/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1666114.0000000ONE YEAR1666114.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Consolidated Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Treatment of LossesCAPITAL STRUCTUREISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Auditors' Special Report on Related-Party Transactions Mentioning the Absence of New TransactionsCORPORATE GOVERNANCEISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Compensation of Laurent Levy, Chairman of the Management BoardCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Compensation of Anne-Juliette Hermant, Management Board MemberCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Compensation of Bartholomeus van Rhijn, Management Board MemberCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Compensation of Louis Kayitalire, Management Board MemberCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Compensation of Gary Phillips, Chairman of the Supervisory BoardCOMPENSATIONISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Compensation Report of Corporate OfficersCOMPENSATIONISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Remuneration of Supervisory Board Members in the Aggregate Amount of EUR 438,751COMPENSATIONISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Remuneration Policy of Supervisory Board MembersCOMPENSATIONISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Remuneration Policy of Laurent Levy, Chairman of the Management BoardCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Remuneration Policy of Anne-Juliette Hermant, Management Board MemberCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Remuneration Policy of Bartholomeus van Rhijn, Management Board MemberCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Remuneration Policy of Louis Kayitalire, Management Board MemberCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Repurchase of Up to 10 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Decrease in Share Capital via Cancellation of Repurchased SharesCAPITAL STRUCTUREISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Issuance of Equity or Equity-Linked Securities with Preemptive Rights up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Issuance of Equity or Equity-Linked Securities without Preemptive Rights up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of Equity or Equity-Linked Securities for Private Placements up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of Equity or Equity-Linked Securities for One or More Specifically Designated Persons up to 30 Percent of Issued Share CapitalCAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries in the Framework of an Equity Line, up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Specific Beneficiaries in the Framework of an Equity Line on the American Market (ATM Program) up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Qualified Investors Active in the Health or Biotechnology Sector and Financial Institutions, up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of Equity or Equity-Linked Securities Reserved for Industrial Companies, Institutions or Entities Active in the Health or Biotechnology Sector, up to Aggregate Nominal Amount of EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Board to Increase Capital in the Event of Additional Demand Related to Delegation Submitted to Shareholder Vote Under Items 19-21, 23 and 25-26CAPITAL STRUCTUREISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Capital Increase of Up to EUR 1,452,302.54 for Future Exchange OffersCAPITAL STRUCTUREISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Capital Increase of up to 20 Percent of Issued Capital for Contributions in KindCAPITAL STRUCTUREISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 19-21, 23, 25-29 and 38 at EUR 1,452,302.54CAPITAL STRUCTUREISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Capitalization of Reserves of Up to EUR 25,000 for Bonus Issue or Increase in Par ValueCAPITAL STRUCTUREISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Up to 1,800,000 Shares for Use in Stock Option PlansCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize up to 1,800,000 Shares for Use in Restricted Stock PlansCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Approve Issuance of up to 1,800,000 Warrants (BSA) Reserved for Specific BeneficiariesCOMPENSATIONISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Set Total Limit for Capital Increase to Result from Issuance Requests Under Items 32-34 at 1,800,000 SharesCOMPENSATIONISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Amend Article 22 of Bylaws to Incorporate Legal Changes Re: Electronic Notification of Shareholders and Record DateCORPORATE GOVERNANCEISSUER196006.0000000FOR196006.000000FORS000002088Nanobiotix SAF64308111FR001134120506/09/2026Amend Article 8 of Bylaws Re: Shareholding Disclosure ThresholdsSHAREHOLDER RIGHTS AND DEFENSESISSUER196006.0000000AGAINST196006.000000AGAINSTS000002088Nanobiotix SAF64308111FR001134120506/09/2026Authorize Capital Issuances for Use in Employee Stock Purchase PlansCOMPENSATIONISSUER196006.0000000FOR196006.000000AGAINSTS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/09/2026Election of Class II directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Antal DesaiDIRECTOR ELECTIONSISSUER246211.0000000FOR246211.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/09/2026Election of Class II directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Mary GarrettDIRECTOR ELECTIONSISSUER246211.0000000FOR246211.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/09/2026Election of Class II directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Frederic Moll, M.D.DIRECTOR ELECTIONSISSUER246211.0000000FOR246211.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/09/2026Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER246211.0000000FOR246211.000000FORS000002088PROCEPT BioRobotics Corporation74276L105US74276L105206/09/2026Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER246211.0000000FOR246211.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/09/2026To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Douglas S. IngramDIRECTOR ELECTIONSISSUER1385862.0000000FOR1385862.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/09/2026To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Claire Mazumdar, Ph.D.DIRECTOR ELECTIONSISSUER1385862.0000000FOR1385862.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/09/2026To consider and act upon an advisory vote on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1385862.0000000FOR1385862.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/09/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER1385862.0000000FOR1385862.000000FORS000002088Relay Therapeutics, Inc.75943R102US75943R102306/09/2026To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 300,000,000 to 450,000,000; andCAPITAL STRUCTUREISSUER1385862.0000000FOR1385862.000000FORS000002088BillionToOne, Inc.090168105US090168105806/10/2026Election of Directors: Oguzhan AtayDIRECTOR ELECTIONSISSUER257875.0000000FOR257875.000000FORS000002088BillionToOne, Inc.090168105US090168105806/10/2026Election of Directors: Akshay RaiDIRECTOR ELECTIONSISSUER257875.0000000FOR257875.000000FORS000002088BillionToOne, Inc.090168105US090168105806/10/2026Ratify the appointment of PricewaterhouseCoopers LLP as BillionToOne, Inc.'s independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER257875.0000000FOR257875.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/10/2026Election of Directors: Peter S. Kim, Ph.D.DIRECTOR ELECTIONSISSUER295981.0000000FOR295981.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/10/2026Election of Directors: Bernhardt Zeiher, M.D.DIRECTOR ELECTIONSISSUER295981.0000000FOR295981.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/10/2026Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER295981.0000000FOR295981.000000FORS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/10/2026Approval of Amendment No. 1 to the Entrada Therapeutics, Inc. 2021 Stock Option and Incentive Plan.COMPENSATIONISSUER295981.0000000AGAINST295981.000000AGAINSTS000002088Entrada Therapeutics, Inc.29384C108US29384C108006/10/2026Approval of Amendment No. 1 to the Entrada Therapeutics, Inc. 2021 Employee Stock Purchase Plan.COMPENSATIONISSUER295981.0000000AGAINST295981.000000AGAINSTS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Iain Dukes, D. Phil.DIRECTOR ELECTIONSISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Athena Countouriotis, M.D.DIRECTOR ELECTIONSISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Ryan MaynardDIRECTOR ELECTIONSISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Wayne P. RothbaumDIRECTOR ELECTIONSISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.DIRECTOR ELECTIONSISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve, by non-binding advisory vote, the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1439842.0000000AGAINST1439842.000000AGAINSTS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;SECTION 14A SAY-ON-PAY VOTESISSUER1439842.0000000ONE YEAR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,000,000 shares;COMPENSATIONISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 500,000,000 shares to 650,000,000 shares; andCAPITAL STRUCTUREISSUER1439842.0000000FOR1439842.000000FORS000002088Iovance Biotherapeutics, Inc.462260100US462260100706/10/2026To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.CORPORATE GOVERNANCEISSUER1439842.0000000AGAINST1439842.000000AGAINSTS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/10/2026To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Pravin U. Dugel, M.D.DIRECTOR ELECTIONSISSUER1432466.0000000FOR1432466.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/10/2026To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Merilee RainesDIRECTOR ELECTIONSISSUER1432466.0000000FOR1432466.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/10/2026To approve an advisory vote on named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1432466.0000000FOR1432466.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/10/2026To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1432466.0000000ONE YEAR1432466.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/10/2026To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 10,000,000 shares.COMPENSATIONISSUER1432466.0000000FOR1432466.000000FORS000002088Ocular Therapeutix, Inc.67576A100US67576A100706/10/2026To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1432466.0000000FOR1432466.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. JenkinsDIRECTOR ELECTIONSISSUER144220.0000000FOR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. DavisDIRECTOR ELECTIONSISSUER144220.0000000FOR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux, M.D.DIRECTOR ELECTIONSISSUER144220.0000000FOR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Ratification of the appointment of Ernst & Young as the Company's independent registered public accounting firm for the 2026 fiscal year.AUDIT-RELATEDISSUER144220.0000000FOR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER144220.0000000FOR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER144220.0000000ONE YEAR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares.COMPENSATIONISSUER144220.0000000FOR144220.000000FORS000002088Palvella Therapeutics, Inc.697947109US697947109006/10/2026Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5.CORPORATE GOVERNANCEISSUER144220.0000000AGAINST144220.000000AGAINSTS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Gregory NordenDIRECTOR ELECTIONSISSUER182301.0000000FOR182301.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Marcio SouzaDIRECTOR ELECTIONSISSUER182301.0000000FOR182301.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William YoungDIRECTOR ELECTIONSISSUER182301.0000000FOR182301.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER182301.0000000FOR182301.000000FORS000002088Praxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTESISSUER182301.0000000FOR182301.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/10/2026To elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II Directors: James Healy, M.D., Ph.D.DIRECTOR ELECTIONSISSUER571905.0000000FOR571905.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/10/2026To elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II Directors: Robert J. PerezDIRECTOR ELECTIONSISSUER571905.0000000FOR571905.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/10/2026To elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II Directors: Raymond Sanchez, M.D.DIRECTOR ELECTIONSISSUER571905.0000000FOR571905.000000FORS000002088Rapport Therapeutics, Inc.75383L102US75383L102606/10/2026To ratify the appointment of PricewaterhouseCoopers LLP as Rapport's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER571905.0000000FOR571905.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Robert W. DugganDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Mahkam ZanganehDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Manmeet S. SoniDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Kenneth A. ClarkDIRECTOR ELECTIONSISSUER6063331.0000000WITHHOLD6063331.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Robert BoothDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Alessandra CesanoDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Yu (Michelle) XiaDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Mostafa RonaghiDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026ELECTION OF DIRECTORS: Jeff HuberDIRECTOR ELECTIONSISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER6063331.0000000FOR6063331.000000FORS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026Approval, by a non-binding advisory vote, of the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER6063331.0000000AGAINST6063331.000000AGAINSTS000002088Summit Therapeutics Inc.86627T108US86627T108806/10/2026Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock.COMPENSATIONISSUER6063331.0000000AGAINST6063331.000000AGAINSTS000002088Aura Biosciences, Inc.05153U107US05153U107906/11/2026To elect two Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: David JohnsonDIRECTOR ELECTIONSISSUER98144.0000000FOR98144.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/11/2026To elect two Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Teresa Marie BitettiDIRECTOR ELECTIONSISSUER98144.0000000FOR98144.000000FORS000002088Aura Biosciences, Inc.05153U107US05153U107906/11/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER98144.0000000FOR98144.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 be and are hereby approved.CORPORATE GOVERNANCEISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the appropriation of the accumulated loss for fiscal year 2025 be and is hereby approved.CAPITAL STRUCTUREISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the members of the Board of Directors and the Executive Management Team be and are hereby discharged from liability for activities during the applicable period under Swiss law.CORPORATE GOVERNANCEISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Olivier Brandicourt be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Margaret Dugan be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Mr. Anthony C. Hooper be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Mr. John V. Oyler be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Alessandro Riva be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088BeOne Medicines Ltd.06/11/2026THAT Ms. Shalini Sharp be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Xiaodong Wang be and is hereby re-elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Felix J. Baker be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Ms. Elizabeth F. Mooney be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Charles L. Sawyers be and is hereby elected to serve as a director of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Mr. John V. Oyler be and is hereby re-elected to serve as Chairman of the Board of Directors of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Dr. Margaret Dugan be and is hereby re-elected to serve as a member of the Compensation Committee of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Ms. Elizabeth F. Mooney be and is hereby elected to serve as a member of the Compensation Committee of the Company for a term extending until completion of the 2027 annual general meeting.DIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT Schweiger Advokatur/Notariat be and is hereby elected to serve as the Independent Voting Representative for a one-year term ending at the closing of the 2027 annual general meeting of shareholders, including any extraordinary general meeting of shareholders prior to the 2027 annual general meeting of shareholders.CORPORATE GOVERNANCEISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 be and is hereby ratified, and Ernst & Young AG be and is hereby re-elected as the Company's statutory auditor for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, for the fiscal year ended December 31, 2025 be and is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT, the maximum aggregate compensation for the Board of Directors for the period between the 2026 annual general meeting and the 2027 annual general meeting, be and is hereby approved.COMPENSATIONISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT, the maximum aggregate compensation for the Executive Management Team for fiscal year 2027 be and is hereby approved.COMPENSATIONISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT, on an advisory basis, the Swiss Statutory Compensation Report for the fiscal year ended December 31, 2025 be and is hereby approved.COMPENSATIONISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT, on an advisory basis, the Swiss Statutory Non-Financial Matters Report for the fiscal year ended December 31, 2025 be and is hereby approved.CORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the Fifth Amended and Restated 2016 Share Option and Incentive Plan be and is hereby approved.COMPENSATIONISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088BeOne Medicines Ltd.06/11/2026THAT the consultant sublimit in the Fifth Amended and Restated 2016 Share Option and Incentive Plan be and is hereby approved.COMPENSATIONISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the Sixth Amended and Restated 2018 Employee Share Purchase Plan be and is hereby approved.COMPENSATIONISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088BeOne Medicines Ltd.06/11/2026THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding the Company's ordinary shares listed on the Science and Technology Innovation Board of Shanghai Stock Exchange and traded in RMB ("RMB shares")) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of this resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.CAPITAL STRUCTUREISSUER2799696.0000000FOR2799696.000000FORS000002088BeOne Medicines Ltd.06/11/2026THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 17 for a period of five years, which period will be subject to an extension on a rolling basis each year.CAPITAL STRUCTUREISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088BeOne Medicines Ltd.06/11/2026THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.CORPORATE GOVERNANCEISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088BeOne Medicines Ltd.06/11/2026If new or modified agenda items (other than those in the invitation to the Annual Meeting and the 2026 Proxy Statement of the Company) or new or modified proposals or motions with respect to the agenda items listed in the invitation to the Annual Meeting and the 2026 Proxy Statement of the Company are presented at the Annual Meeting, I instruct the Independent Voting Representative to vote in favor of the recommendations of the Board (For), against the proposals (Against) or abstain (Abstain) as follows:CORPORATE GOVERNANCEISSUER2799696.0000000AGAINST2799696.000000AGAINSTS000002088Corvus Pharmaceuticals, Inc.221015100US221015100506/11/2026To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Richard A. Miller, M.D.DIRECTOR ELECTIONSISSUER616391.0000000FOR616391.000000FORS000002088Corvus Pharmaceuticals, Inc.221015100US221015100506/11/2026To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Linda S. Grais, M.D. J.D.DIRECTOR ELECTIONSISSUER616391.0000000FOR616391.000000FORS000002088Corvus Pharmaceuticals, Inc.221015100US221015100506/11/2026To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER616391.0000000FOR616391.000000FORS000002088Corvus Pharmaceuticals, Inc.221015100US221015100506/11/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER616391.0000000FOR616391.000000FORS000002088Immuneering Corporation45254E107US45254E107306/11/2026Election of two Class II Directors: Peter FeinbergDIRECTOR ELECTIONSISSUER387692.0000000FOR387692.000000FORS000002088Immuneering Corporation45254E107US45254E107306/11/2026Election of two Class II Directors: Laurie B. KeatingDIRECTOR ELECTIONSISSUER387692.0000000FOR387692.000000FORS000002088Immuneering Corporation45254E107US45254E107306/11/2026Ratify the appointment of RSM US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER387692.0000000FOR387692.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Andrew Schiff, M.D.DIRECTOR ELECTIONSISSUER1935310.0000000FOR1935310.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Chandra P. Leo, M.D.DIRECTOR ELECTIONSISSUER1935310.0000000FOR1935310.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/11/2026To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Anthony Manning, Ph.D.DIRECTOR ELECTIONSISSUER1935310.0000000FOR1935310.000000FORS000002088Monte Rosa Therapeutics, Inc.61225M102US61225M102706/11/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER1935310.0000000FOR1935310.000000FORS000002088Natera, Inc.632307104US632307104206/11/2026To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. Class II Nominees: Rowan ChapmanDIRECTOR ELECTIONSISSUER561746.0000000WITHHOLD561746.000000AGAINSTS000002088Natera, Inc.632307104US632307104206/11/2026To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. Class II Nominees: Herm RosenmanDIRECTOR ELECTIONSISSUER561746.0000000WITHHOLD561746.000000AGAINSTS000002088Natera, Inc.632307104US632307104206/11/2026To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. Class II Nominees: Jonathan SheenaDIRECTOR ELECTIONSISSUER561746.0000000WITHHOLD561746.000000AGAINSTS000002088Natera, Inc.632307104US632307104206/11/2026To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. Class I Nominee: Eric H. RubinDIRECTOR ELECTIONSISSUER561746.0000000FOR561746.000000FORS000002088Natera, Inc.632307104US632307104206/11/2026To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER561746.0000000FOR561746.000000FORS000002088Natera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER561746.0000000FOR561746.000000FORS000002088Natera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER561746.0000000ONE YEAR561746.000000FORS000002088Natera, Inc.632307104US632307104206/11/2026To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated.COMPENSATIONISSUER561746.0000000FOR561746.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Election of Directors: Joseph L. Goldstein, M.D.DIRECTOR ELECTIONSISSUER372826.0000000FOR372826.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Election of Directors: Christine A. PoonDIRECTOR ELECTIONSISSUER372826.0000000FOR372826.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Election of Directors: David P. Schenkein, M.D.DIRECTOR ELECTIONSISSUER372826.0000000FOR372826.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Election of Directors: Craig B. Thompson, M.D.DIRECTOR ELECTIONSISSUER372826.0000000FOR372826.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Election of Directors: Huda Y. Zoghbi, M.D.DIRECTOR ELECTIONSISSUER372826.0000000FOR372826.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER372826.0000000FOR372826.000000FORS000002088Regeneron Pharmaceuticals, Inc.75886F107US75886F107506/12/2026Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.SECTION 14A SAY-ON-PAY VOTESISSUER372826.0000000FOR372826.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSciDIRECTOR ELECTIONSISSUER472316.0000000FOR472316.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: William FaireyDIRECTOR ELECTIONSISSUER472316.0000000FOR472316.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy WalbertDIRECTOR ELECTIONSISSUER472316.0000000FOR472316.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER472316.0000000FOR472316.000000FORS000002088Mirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER472316.0000000FOR472316.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/15/2026Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D.DIRECTOR ELECTIONSISSUER335245.0000000FOR335245.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/15/2026Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Halley Gilbert, J.D.DIRECTOR ELECTIONSISSUER335245.0000000FOR335245.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/15/2026Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Grant E. Pickering, M.B.A.DIRECTOR ELECTIONSISSUER335245.0000000FOR335245.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/15/2026Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER335245.0000000FOR335245.000000FORS000002088Vaxcyte, Inc.92243G108US92243G108506/15/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER335245.0000000FOR335245.000000FORS000002088Bridgebio Oncology Therapeutics, Inc.107924102US107924102206/16/2026To elect two Class I directors to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Frank McCormick, Ph.D., F.R.S., D.Sc.DIRECTOR ELECTIONSISSUER222512.0000000FOR222512.000000FORS000002088Bridgebio Oncology Therapeutics, Inc.107924102US107924102206/16/2026To elect two Class I directors to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Peter Lebowitz, M.D., Ph.D.DIRECTOR ELECTIONSISSUER222512.0000000FOR222512.000000FORS000002088Bridgebio Oncology Therapeutics, Inc.107924102US107924102206/16/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER222512.0000000FOR222512.000000FORS000002088Cullinan Therapeutics, Inc.230031106US230031106306/16/2026Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Nadim AhmedDIRECTOR ELECTIONSISSUER583803.0000000FOR583803.000000FORS000002088Cullinan Therapeutics, Inc.230031106US230031106306/16/2026Election of the following individuals nominated to serve as Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2029: Stephen WebsterDIRECTOR ELECTIONSISSUER583803.0000000FOR583803.000000FORS000002088Cullinan Therapeutics, Inc.230031106US230031106306/16/2026Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER583803.0000000FOR583803.000000FORS000002088Cullinan Therapeutics, Inc.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER583803.0000000FOR583803.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Yujiro S. HataDIRECTOR ELECTIONSISSUER232971.0000000FOR232971.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: M. Garret Hampton, Ph.D.DIRECTOR ELECTIONSISSUER232971.0000000FOR232971.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Catherine J. Mackey, Ph.D.DIRECTOR ELECTIONSISSUER232971.0000000FOR232971.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER232971.0000000FOR232971.000000FORS000002088IDEAYA Biosciences, Inc.45166A102US45166A102506/16/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; andSECTION 14A SAY-ON-PAY VOTESISSUER232971.0000000FOR232971.000000FORS000002088Liquidia Corporation53635D202US53635D202706/16/2026Election of Directors: David JohnsonDIRECTOR ELECTIONSISSUER221552.0000000FOR221552.000000FORS000002088Liquidia Corporation53635D202US53635D202706/16/2026Election of Directors: Katie Rielly-GauvinDIRECTOR ELECTIONSISSUER221552.0000000FOR221552.000000FORS000002088Liquidia Corporation53635D202US53635D202706/16/2026Election of Directors: Ramandeep SinghDIRECTOR ELECTIONSISSUER221552.0000000FOR221552.000000FORS000002088Liquidia Corporation53635D202US53635D202706/16/2026To ratify the Appointment of PricewaterhouseCoopers LLP as the Company's Independent Registered Public Accounting Firm for the Year Ending December 31, 2026.AUDIT-RELATEDISSUER221552.0000000FOR221552.000000FORS000002088Liquidia Corporation53635D202US53635D202706/16/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER221552.0000000FOR221552.000000FORS000002088Nuvalent, Inc.670703107US670703107506/16/2026Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.DIRECTOR ELECTIONSISSUER459791.0000000FOR459791.000000FORS000002088Nuvalent, Inc.670703107US670703107506/16/2026Election of the following nominees as Class II directors: Ron SquarerDIRECTOR ELECTIONSISSUER459791.0000000FOR459791.000000FORS000002088Nuvalent, Inc.670703107US670703107506/16/2026To approve, on an advisory basis, the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER459791.0000000FOR459791.000000FORS000002088Nuvalent, Inc.670703107US670703107506/16/2026To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER459791.0000000FOR459791.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Accept Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Approve Non-Financial ReportCORPORATE GOVERNANCEENVIRONMENT OR CLIMATEHUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCEDIVERSITY, EQUITY, AND INCLUSIONOTHER SOCIAL ISSUESISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Approve Allocation of Income and Dividends of CHF 4.70 per ShareCAPITAL STRUCTUREISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Approve Discharge of Board and Senior ManagementCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Approve Remuneration Report (Non-Binding)COMPENSATIONISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Approve Remuneration of Directors in the Amount of CHF 3.4 MillionCOMPENSATIONISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Approve Remuneration of Executive Committee in the Amount of CHF 17.6 MillionCOMPENSATIONISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reelect Gilbert Achermann as Director and Board ChairDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reelect Gregory Behar as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reelect Roland Diggelmann as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reelect Laura Stoltenberg as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reelect Julie Tay as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reelect Adrian Widmer as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Elect Ingrid Cotoros as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Elect Malina Ngai as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Elect Hooi Tan as DirectorDIRECTOR ELECTIONSISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reappoint Roland Diggelmann as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reappoint Gregory Behar as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Reappoint Julie Tay as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Appoint Malina Ngai as Member of the Nomination and Compensation CommitteeDIRECTOR ELECTIONSCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Ratify Ernst & Young AG as AuditorsAUDIT-RELATEDISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Designate Keller AG as Independent ProxyCORPORATE GOVERNANCEISSUER72348.0000000FOR72348.000000FORS000002088Sonova Holding AGH8024W106CH001254978506/16/2026Transact Other Business (Voting)CORPORATE GOVERNANCEISSUER72348.0000000AGAINST72348.000000AGAINSTS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. DahiyatDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Raymond J. DeshaiesDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. FeigalDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. GormanDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. GustafsonDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara KlenckeDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce MontgomeryDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. RanieriDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Election of the nine nominees to the Board named in this Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Todd E. SimpsonDIRECTOR ELECTIONSISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Ratification of selection by the Audit Committee of the Board of KPMG LLP as independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Approval of the amendment to the Company's Amended and Restated 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 4,000,000 shares; andCOMPENSATIONISSUER340341.0000000FOR340341.000000FORS000002088Xencor, Inc.98401F105US98401F105706/16/2026Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers, as disclosed in this Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER340341.0000000FOR340341.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To re-elect as a director Felix Baker, who retires in accordance with the Articles of Association.DIRECTOR ELECTIONSISSUER628421.0000000AGAINST628421.000000AGAINSTS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To re-elect as a director Herve Hoppenot, who retires in accordance with the Articles of Association.DIRECTOR ELECTIONSISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as our U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders.AUDIT-RELATEDISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To authorize the Audit Committee to determine our U.K. statutory auditors' remuneration for the year ending December 31, 2026.AUDIT-RELATEDISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To receive and adopt our U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the "2025 U.K. Annual Report").CORPORATE GOVERNANCEISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To approve our directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the proxy statement (excluding the directors' remuneration policy set out on pages A-3 to A-22 of the directors' remuneration report and referenced in Proposal 9).COMPENSATIONISSUER628421.0000000FOR628421.000000FORS000002088Bicycle Therapeutics Plc088786108US088786108806/17/2026To approve the directors' remuneration policy, which is set out on pages A-3 to A-22 of Annex A to the proxy statement.COMPENSATIONISSUER628421.0000000FOR628421.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/17/2026Election of Class II Directors: Ian ClarkDIRECTOR ELECTIONSISSUER1055988.0000000FOR1055988.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/17/2026Election of Class II Directors: Manuel Hidalgo MedinaDIRECTOR ELECTIONSISSUER1055988.0000000FOR1055988.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/17/2026Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER1055988.0000000FOR1055988.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/17/2026Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1055988.0000000FOR1055988.000000FORS000002088Guardant Health, Inc.40131M109US40131M109906/17/2026Non-binding advisory vote on the frequency of stockholder advisory votes regarding compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1055988.0000000ONE YEAR1055988.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Re-election of Class I directors: Julian BakerDIRECTOR ELECTIONSISSUER60884.0000000WITHHOLD60884.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Re-election of Class I directors: Daniel BrennanDIRECTOR ELECTIONSISSUER60884.0000000FOR60884.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Re-election of Class I directors: James DalyDIRECTOR ELECTIONSISSUER60884.0000000WITHHOLD60884.000000AGAINSTS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTESISSUER60884.0000000FOR60884.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026AUDIT-RELATEDISSUER60884.0000000FOR60884.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Approval of Madrigal Pharmaceuticals, Inc. 2026 Stock PlanCOMPENSATIONISSUER60884.0000000FOR60884.000000FORS000002088Madrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Approval of Madrigal Pharmaceuticals, Inc. 2026 Employee Stock Purchase PlanCOMPENSATIONISSUER60884.0000000FOR60884.000000FORS000002088Olema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Sean Bohen, M.D., Ph.D.DIRECTOR ELECTIONSISSUER583617.0000000FOR583617.000000FORS000002088Olema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Scott GarlandDIRECTOR ELECTIONSISSUER583617.0000000FOR583617.000000FORS000002088Olema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Yi LarsonDIRECTOR ELECTIONSISSUER583617.0000000FOR583617.000000FORS000002088Olema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Election of the four nominees for Class III director named in the accompanying proxy statement to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Andrew RappaportDIRECTOR ELECTIONSISSUER583617.0000000FOR583617.000000FORS000002088Olema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER583617.0000000FOR583617.000000FORS000002088Olema Pharmaceuticals, Inc.68062P106US68062P106606/17/2026Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER583617.0000000FOR583617.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dinesh V. Patel, Ph.D.DIRECTOR ELECTIONSISSUER1162259.0000000FOR1162259.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1162259.0000000WITHHOLD1162259.000000AGAINSTS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER1162259.0000000FOR1162259.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1162259.0000000FOR1162259.000000FORS000002088Protagonist Therapeutics, Inc.74366E102US74366E102906/17/2026To approve the adoption of the Company's 2026 Equity Incentive Plan.COMPENSATIONISSUER1162259.0000000FOR1162259.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/17/2026To elect four class II directors to serve until our 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: H. Edward Fleming, Jr., M.D.DIRECTOR ELECTIONSISSUER518443.0000000FOR518443.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/17/2026To elect four class II directors to serve until our 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Marcella Kuhlman Ruddy, M.D.DIRECTOR ELECTIONSISSUER518443.0000000FOR518443.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/17/2026To elect four class II directors to serve until our 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Peter A. Thompson, M.D.DIRECTOR ELECTIONSISSUER518443.0000000FOR518443.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/17/2026To elect four class II directors to serve until our 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Joanne Louise Viney, Ph.D.DIRECTOR ELECTIONSISSUER518443.0000000FOR518443.000000FORS000002088Sionna Therapeutics, Inc.829401108US829401108006/17/2026To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER518443.0000000FOR518443.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/17/2026Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Ted W. Love, M.D.DIRECTOR ELECTIONSISSUER1276807.0000000FOR1276807.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/17/2026Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Raymond Stevens, Ph.D.DIRECTOR ELECTIONSISSUER1276807.0000000FOR1276807.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/17/2026Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Daniel G. WelchDIRECTOR ELECTIONSISSUER1276807.0000000FOR1276807.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/17/2026To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1276807.0000000FOR1276807.000000FORS000002088Structure Therapeutics Inc.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER1276807.0000000FOR1276807.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Samantha (Ying) DuDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: John D. DiekmanDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Richard GaynorDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Nisa LeungDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: William LisDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Scott MorrisonDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Leon O. Moulder, Jr.DIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Michel VounatsosDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, each director nominee identified below is hereby re-elected to serve as a director until the 2027 annual general meeting of shareholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal: Peter WirthDIRECTOR ELECTIONSISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, the appointment of KPMG LLP and KPMG as the Company's independent registered public accounting firms and auditors to audit the Company's consolidated financial statements to be filed with the U.S. Securities and Exchange Commission and The Stock Exchange of Hong Kong Limited for the year ending December 31, 2026, respectively, is hereby approved.AUDIT-RELATEDISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, the authority of the Board of Directors to fix auditor compensation for 2026, is hereby approved.AUDIT-RELATEDISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved.SECTION 14A SAY-ON-PAY VOTESISSUER181214.0000000AGAINST181214.000000AGAINSTS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs and/or resell treasury shares of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2027 annual general meeting of shareholders is hereby approved.CAPITAL STRUCTUREISSUER181214.0000000FOR181214.000000FORS000002088Zai Lab Limited98887Q104US98887Q104006/17/2026THAT, a general mandate to repurchase ordinary shares and/or ADSs of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2027 annual general meeting of shareholders, is hereby approved.CAPITAL STRUCTUREISSUER181214.0000000FOR181214.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Rahul Ballal, Ph.D.DIRECTOR ELECTIONSISSUER93727.0000000FOR93727.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Brian GoffDIRECTOR ELECTIONSISSUER93727.0000000FOR93727.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia SmithDIRECTOR ELECTIONSISSUER93727.0000000FOR93727.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To vote, on an advisory basis, to approve the compensation paid to our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER93727.0000000FOR93727.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To approve an amendment to the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan, as Amended, to increase the number of shares of common stock available thereunder by 2,000,000 shares.COMPENSATIONISSUER93727.0000000FOR93727.000000FORS000002088Agios Pharmaceuticals, Inc.00847X104US00847X104606/18/2026To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER93727.0000000FOR93727.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026Election of Directors: Deborah MessemerDIRECTOR ELECTIONSISSUER3444101.0000000FOR3444101.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026Election of Directors: Vicki Sato, Ph.D.DIRECTOR ELECTIONSISSUER3444101.0000000FOR3444101.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026Election of Directors: Owen Witte, M.D.DIRECTOR ELECTIONSISSUER3444101.0000000FOR3444101.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER3444101.0000000FOR3444101.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3444101.0000000ONE YEAR3444101.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.CAPITAL STRUCTUREISSUER3444101.0000000FOR3444101.000000FORS000002088Allogene Therapeutics, Inc.019770106US019770106506/18/2026To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER3444101.0000000FOR3444101.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Caren DeardorfDIRECTOR ELECTIONSISSUER1095356.0000000FOR1095356.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Weston Nichols, Ph.D.DIRECTOR ELECTIONSISSUER1095356.0000000FOR1095356.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Stephanie S. Okey, M.S.DIRECTOR ELECTIONSISSUER1095356.0000000FOR1095356.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To ratify the selection of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm for the fiscal year ending December 31, 2026;AUDIT-RELATEDISSUER1095356.0000000FOR1095356.000000FORS000002088Crinetics Pharmaceuticals, Inc.22663K107US22663K107906/18/2026To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; andSECTION 14A SAY-ON-PAY VOTESISSUER1095356.0000000FOR1095356.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/18/2026To elect each of the following Class III nominees to the Board of Directors as set forth below: Class III Nominees: Donald Nicholson, Ph.D.DIRECTOR ELECTIONSISSUER167759.0000000FOR167759.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/18/2026To elect each of the following Class III nominees to the Board of Directors as set forth below: Class III Nominees: John Quisel, J.D., Ph.D.DIRECTOR ELECTIONSISSUER167759.0000000FOR167759.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/18/2026To elect each of the following Class III nominees to the Board of Directors as set forth below: Class III Nominees: William White, M.P.P., J.D.DIRECTOR ELECTIONSISSUER167759.0000000FOR167759.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/18/2026To approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER167759.0000000FOR167759.000000FORS000002088Disc Medicine, Inc.254604101US254604101106/18/2026To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER167759.0000000FOR167759.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER321364.0000000FOR321364.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER321364.0000000FOR321364.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Reelect H. Singh Jasuja as Executive Director IIIDIRECTOR ELECTIONSISSUER321364.0000000FOR321364.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Reelect M.P. Hothum as Non-Executive Director IIIDIRECTOR ELECTIONSISSUER321364.0000000FOR321364.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Reelect A.L. Stone as Non-Executive Director IIIDIRECTOR ELECTIONSISSUER321364.0000000FOR321364.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Authorize Repurchase of Ordinary Shares or Depositary ReceiptsCAPITAL STRUCTUREISSUER321364.0000000FOR321364.000000FORS000002088Immatics N.V.N44445109NL001528594106/18/2026Approve 2026 Stock Option and Incentive PlanCOMPENSATIONISSUER321364.0000000AGAINST321364.000000AGAINSTS000002088Immatics N.V.N44445109NL001528594106/18/2026Ratify PricewaterhouseCoopers Accountants N.V. as AuditorsAUDIT-RELATEDISSUER321364.0000000FOR321364.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Jacob M. Chacko, M.D.DIRECTOR ELECTIONSISSUER1533122.0000000FOR1533122.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Mardi C. DierDIRECTOR ELECTIONSISSUER1533122.0000000FOR1533122.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1533122.0000000FOR1533122.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To approve the ORIC Pharmaceuticals, Inc. 2020 Equity Incentive Plan, as amended and restated.COMPENSATIONISSUER1533122.0000000AGAINST1533122.000000AGAINSTS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To approve, on an advisory basis, executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1533122.0000000FOR1533122.000000FORS000002088ORIC Pharmaceuticals, Inc.68622P109US68622P109306/18/2026To approve, on an advisory basis, the frequency of future advisory votes on executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER1533122.0000000ONE YEAR1533122.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/18/2026To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Alexis BorisyDIRECTOR ELECTIONSISSUER1363591.0000000FOR1363591.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/18/2026To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Mark A. Goldsmith, M.D., Ph.D.DIRECTOR ELECTIONSISSUER1363591.0000000FOR1363591.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/18/2026To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; andAUDIT-RELATEDISSUER1363591.0000000FOR1363591.000000FORS000002088Revolution Medicines, Inc.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER1363591.0000000FOR1363591.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: James C. MomtazeeDIRECTOR ELECTIONSISSUER834349.0000000FOR834349.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Frank P. McCormick, Ph.D.DIRECTOR ELECTIONSISSUER834349.0000000FOR834349.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly elected and qualified: Hannah A. Valantine, M.D.DIRECTOR ELECTIONSISSUER834349.0000000FOR834349.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTESISSUER834349.0000000FOR834349.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER834349.0000000ONE YEAR834349.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER834349.0000000FOR834349.000000FORS000002088BridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.COMPENSATIONISSUER834349.0000000FOR834349.000000FORS000002088Wave Life Sciences Ltd.Y95308105SG999901471606/22/2026To approve the scheme of arrangement under Singapore law among Wave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore ("Wave-Singapore"), the shareholders of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation, subject to approval of the High Court of the Republic of Singapore, as set forth in Wave-Singapore's notice of, and proxy statement relating to, the Special Meeting of Wave-Singapore shareholders.EXTRAORDINARY TRANSACTIONSISSUER2106633.0000000FOR2106633.000000FORS000002088MapLight Therapeutics, Inc.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Martin BablerDIRECTOR ELECTIONSISSUER42357.0000000FOR42357.000000FORS000002088MapLight Therapeutics, Inc.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Troy CoxDIRECTOR ELECTIONSISSUER42357.0000000FOR42357.000000FORS000002088MapLight Therapeutics, Inc.56565P103US56565P103006/23/2026To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: George PavlovDIRECTOR ELECTIONSISSUER42357.0000000FOR42357.000000FORS000002088MapLight Therapeutics, Inc.56565P103US56565P103006/23/2026To ratify the appointment by the Audit Committee of our Board of Directors of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER42357.0000000FOR42357.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/24/2026To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil.DIRECTOR ELECTIONSISSUER1065867.0000000FOR1065867.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/24/2026To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Nello Mainolfi, Ph.D.DIRECTOR ELECTIONSISSUER1065867.0000000FOR1065867.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/24/2026To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Maraganore, Ph.D.DIRECTOR ELECTIONSISSUER1065867.0000000FOR1065867.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/24/2026To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFADIRECTOR ELECTIONSISSUER1065867.0000000FOR1065867.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/24/2026To approve, on a non-binding advisory basis, the compensation of our named executive officers; andSECTION 14A SAY-ON-PAY VOTESISSUER1065867.0000000FOR1065867.000000FORS000002088Kymera Therapeutics, Inc.501575104US501575104406/24/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1065867.0000000FOR1065867.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2026Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David W.J. McGirrDIRECTOR ELECTIONSISSUER241658.0000000FOR241658.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2026Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David P. Meeker, M.D.DIRECTOR ELECTIONSISSUER241658.0000000FOR241658.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2026Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER241658.0000000FOR241658.000000FORS000002088Rhythm Pharmaceuticals, Inc.76243J105US76243J105106/24/2026Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTESISSUER241658.0000000FOR241658.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Harry H. Penner, Jr.DIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Anthony S. MarucciDIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Keith L. BrownlieDIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Cheryl L. CohenDIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Herbert J. ConradDIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Rita I. Jain, M.D.DIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: James J. MarinoDIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Garry A. Neil, M.D.DIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026Election of Directors: Denice TorresDIRECTOR ELECTIONSISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026.AUDIT-RELATEDISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 3,400,000 shares to 12,900,000 shares and a clarification regarding the tax withholding provisions applicable to awards under the 2021 Incentive Plan.COMPENSATIONISSUER494692.0000000FOR494692.000000FORS000002088Celldex Therapeutics, Inc.15117B202US15117B202506/25/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER494692.0000000FOR494692.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Wendy YarnoDIRECTOR ELECTIONSISSUER158096.0000000FOR158096.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Andrew GoldbergDIRECTOR ELECTIONSISSUER158096.0000000FOR158096.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: Scott MorrisonDIRECTOR ELECTIONSISSUER158096.0000000FOR158096.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed: David E.I. PyottDIRECTOR ELECTIONSISSUER158096.0000000FOR158096.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTESISSUER158096.0000000FOR158096.000000FORS000002088Tarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER158096.0000000FOR158096.000000FORS000002088Erasca, Inc.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Alexander W. CasdinDIRECTOR ELECTIONSISSUER1110913.0000000FOR1110913.000000FORS000002088Erasca, Inc.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Julie Hambleton, M.D.DIRECTOR ELECTIONSISSUER1110913.0000000FOR1110913.000000FORS000002088Erasca, Inc.29479A108US29479A108806/26/2026To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Michael D. Varney, Ph.D.DIRECTOR ELECTIONSISSUER1110913.0000000FOR1110913.000000FORS000002088Erasca, Inc.29479A108US29479A108806/26/2026To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026AUDIT-RELATEDISSUER1110913.0000000FOR1110913.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/26/2026Adopt Financial Statements and Statutory ReportsCORPORATE GOVERNANCEISSUER281824.0000000FOR281824.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/26/2026Ratify PricewaterhouseCoopers Accountants N.V. as AuditorsAUDIT-RELATEDISSUER281824.0000000FOR281824.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/26/2026Approve Discharge of DirectorsCORPORATE GOVERNANCEISSUER281824.0000000FOR281824.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/26/2026Authorize Repurchase of Ordinary Shares and Depositary ReceiptsCAPITAL STRUCTUREISSUER281824.0000000FOR281824.000000FORS000002088Pharvaris NVN69605108NL00150005Y406/26/2026Reelect Margareta Elisabeth Bjork as Non-Executive DirectorDIRECTOR ELECTIONSISSUER281824.0000000FOR281824.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Christopher CauseyDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Richard GiltnerDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Ray KurzweilDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Jan MalcolmDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Linda MaxwellDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Nilda MesaDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Judy OlianDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Christopher PatuskyDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Martine RothblattDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Louis SullivanDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Tommy ThompsonDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Election of Directors: Kevin TraceyDIRECTOR ELECTIONSISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTESISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.COMPENSATIONISSUER174613.0000000FOR174613.000000FORS000002088United Therapeutics Corporation91307C102US91307C102706/26/2026Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.AUDIT-RELATEDISSUER174613.0000000FOR174613.000000FORS000002088Alumis Inc.022307102US022307102006/30/2026To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: James B. Tananbaum, M.D.DIRECTOR ELECTIONSISSUER1284723.0000000FOR1284723.000000FORS000002088Alumis Inc.022307102US022307102006/30/2026To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: Lynn Tetrault, J.D.DIRECTOR ELECTIONSISSUER1284723.0000000FOR1284723.000000FORS000002088Alumis Inc.022307102US022307102006/30/2026To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: Zhengbin (Bing) Yao, Ph.D.DIRECTOR ELECTIONSISSUER1284723.0000000FOR1284723.000000FORS000002088Alumis Inc.022307102US022307102006/30/2026To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for the Company's fiscal year ending December 31, 2026.AUDIT-RELATEDISSUER1284723.0000000FOR1284723.000000FORS000002088